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Chapter I 
Introduction and scope of the thesis 

Chapter I 
Introduction 
Approximately one half of all newly diagnosed cancer patients will die of 
metastatic disease despite the application of the best available treatment consisting 
of surgery, radiation therapy and chemotherapy. Attempts to develop new approa-
ches for the treatment of metastatic cancer by stimulating immune host defences 
against the tumor have received substantial attention. Initially most efforts to 
develop immunotherapies have involved nonspecific stimulation of the immune 
system with unspecific immunostimulants such as Bacille Calmette Guerin or 
Corynebacterium parvum. However, clinical trials have been disappointing and this 
immunotherapeutic approach has been abandoned. An alternative approach is that 
of adoptive immunotherapy, which is defined as the transfer of immunologic 
reagents or immune cells with antitumor reactivity to the tumor bearing host (I). 
Interleukin-2 (lL2), formerly called "T cell growth factor", is a naturally 
occurring glycoprotein, first identitled in 1976 (2,3). It is synthesized and released 
by activated T lymphocytes of the helper subset (2,4). IL2 acts as a pleiotropic 
mediator within the immune system, having a variety of effects via specific cell 
surface receptors. In vitro activities of IL2 include long-term proliferation of 
activated T cell clones, enhancement of lymphocyte mitogenesis, induction of T 
cell reactivity, augmentation of natural killer (NK) cell activity and induction of 
Iymphokine-activated killer (LAK) activity (5-11). LAK cells are effector cells 
capable of lysing autologous and allogeneic tumor cell lines and fresh tumor. DNA 
technology has made it possible to clone the gene for IL2 and insert it into 
Escherichia coli to produce large amounts of recombinant interleukin-2 (12). When 
IL2 is injected in vivo it leads to the production of secondary cytokines, including 
ILl, TNPa, IFN'Y, IL6, GM-CSP and M-CSP (13-15). These cytotoxic and 
antiproliferative cytokines may partly be responsible for the antitumor activity of 
IL2 (6,7,16-18). In animal studies IL2 mediates the regression of pulmonary and 
liver metastases from a variety of tumors (19). 
These observations have led to clinical investigations with IL2 alone or in 
combination with LAK. It was shown that renal cell cancer and melanoma were the 
most sensitive tumors. The tlrst results were published by Rosenberg et al (20-22). 
The first used schedule consisted of a high-dose intravenous bolus regimen, 
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impressive responses were seen in up to 35 % of patients (20-22). The side effects 
of high-dose intermittent doses of IL2 were substantial, including fever, chills, skin 
rash, anorexia, nausea, _ vomiting, diarrhea, hypotension, oliguria, weight gain, lung 
edema and cardiac rhythm disturbances (20-22). 
In contrast to this high-dose bolus regimen, West et al introduced a schedule of 
continuous intravenous administration of IL2 18 MIU/m'/day for 5 days and early 
studies suggested that IL2 by continuous infusion could also yield good antitumor 
activity with decreased toxicity (52,53). In the past years a great number of studies, 
administering high-dose IL2 alone or combined with LAK cells in a wide variety of 
schedules, have been published (25-41). In patients with metastatic renal cell cancer 
or melanoma response rates of 10-25 % have been reported. 
Interferon-alpha is produced by leukocytes upon stimulation by a virus and was 
originally detected by its ability to mediate in vitro antiviral activity (41). IFN" has 
a direct antiproliferative effect on tumor cells in vitro (42-44). It upregulates the 
expression of major histocompatibility complex (MHC) antigens class I and II, {3-
microglobulin as well as tumor associated antigens (42,43,45,46). The stimulated 
expression of tumor antigens may make neoplastic cells more susceptible to 
cytotoxicity by T cells of the host. IFN" has the ability to modulate the host-
immune system by augmenting the activity of mature NK cells and by promoting 
their differentiation from precursors (43). Stimulation of NK cells may result in 
lysis of tumor cells. The development of cytotoxic T lymphocytes, monocytes and 
macrophages is enhanced by IFN" (43,44,46). 
The antitumor activity of IFN" in vivo has been demonstrated in various 
mouse models (47). In patients IFN" has the highest antitumor activity in hemato-
logical malignancies, followed by metastatic renal cell cancer and melanoma with 
response rates of approximately 15-20% (48-53). 
Several strategies have been proposed for improving the antitumor activity of 
immunotherapy with cytokines. There has been considerable interest in the 
combination of IL2 and IFN" for cancer treatment. Several animal experiments 
have shown that the combination of IL2 and IFN" enhances effector-cell mecha-
nisms and produces superior antitumor activity when compared with the maximum-
tolerated dose of the single agents in the same tumor models (54-57). Based on the 
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conducted. A phase I trial of high-dose IL2 and IFN", by bolus injections perfor-
med by the NCI Surgery Branch produced response rates of 31 % and 33% in 
patients with renal cell cancer and melanoma, respectively (58). Also other early 
clinical studies yielded encouraging response rates of up to 40% (59-61). 
Scope of the thesis 
The above mentioned observations of synergy between IL2 and IFN", in 
laboratory experiments and the encouraging initial treatment results of clinical 
phase I studies form the rationale for further investigations of immunotherapy 
based on various combination schedules of IL2 and IFN",. This thesis describes the 
results of phase II studies of IL2 and IFN", in patients with metastatic renal cell 
cancer and melanoma. The primary objective was to determine the response rate 
and the median duration of response. A second objective was to assess the toxici-
ties associated with these combination schedules. 
Chapter 2 describes our initial experience with the combined treatment of IL2 
and IFN", in patients with metastatic melanoma, whereas in Chapter 3 the final 
analysis of this large European phase II study is reported. In this study patients 
received intermediate high doses of ILl (7.8 MIU/m'/day) and IFN", (6 
MU/m'/day) every other week. The treatment schedule was derived from a 
regimen developed by Sondel et al (62). They found that IL2 administration each 
week for 4 days resulted in a progressive increase of the rebound lymphocyte count 
at the completion of each cycle and that these lymphocytes demonstrated a 100-fold 
increase in cytotoxic potential. 
In a dose escalating study Rosenberg et al found a dose-response relationship 
for the combination of IL2 and IFN", with response rates as high as 40% (58) In an 
attempt to confirm these results we carried out a trial in melanoma patients, 
administering high dose IL2 (11.7 MIU/m'/day) and IFN", (3 MU/m'/day) by 
intravenous bolus three times a day. The results of this study are presented in 
Chapter 4. 
Initial studies suggested that the combination of IL2 and lymphokine-activated 
killer cells (LAK) was superior to ILl alone. Consequently, we designed a study of 
13 
Chapter I 
IL2, IFNa, and LAK in patients with metastatic renal cell cancer. The final 
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Chapter 6 describes the high incidence and the severe nature of cardiotoxicity, 
observed in patients with metastatic melanoma treated with high-dose bolus IL2 and 
IFNa as reported in Chapter 4. 
Several investigators have attempted to identify prognostic factors that predict a 
response to IL2-based immunotherapy. Some authors have suggested that the 
occurrence of hypothyroidism is positively related to clinical response (63). In 
Chapter 7 the incidence of thyroid dysfunction related to various treatment schedu-
les is reported and the significance of thyroid dysfunction as a prognostic factor is 
analyzed. 
In chapter 8 the present role of adoptive immunotherapy with IL2 and IFNa is 
discussed with special attention to new innovative treatment modalities and future 
perspectives that become available. 
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Summary 
A multicenter study of IL2 and IFNI> has been performed in 58 patients with 
metastatic melanoma. The scheme consisted of IL2 3.0 BRMP MU/m'/day as a 
continuous infusion for 4 days combined with subcutaneous administration of IFN", 
6 MU/m'/day, day 1 + 4. The cycle was repeated every 2 weeks for a maximum 
duration of 26 weeks. 54 patients were evaluable for response. One (2 %) achieved 
a complete and 10 (19%) a partial response. 19 (35%) patients were stable and 24 
(44 %) showed progressive disease. Common side effects included fever, chills, 
fatigue, skin rash, anorexia, nausea and diarrhea. Hypothyroidism was noted in 
10% of the patients. These results show that this regimen of IL2 and IFN", is 
active but, in contrast to what could be expected, not superior to IL2 alone possibly 
due to suboptimal dosing. 
In an ongoing study in Rotterdam and Nijmegen, a more intense schedule was 
chosen, consisting of three daily i.v. doses of IL2 4.5 BRMP MUlm' and IFNI> 
3.0 MU/m' for 5 days. This regimen was repeated at intervals of 3 weeks for a 
total of three cycles. Presently, nine patients have been entered. One patient 
achieved a complete response, four a partial response (overall 56%), three had 
stable disease and one progressed. Toxicity was severe and treatment was 
prematurely stopped in five patients: myocarcial infarction (one patient), atrial 
fibrillation (one patient), negative T waves and myocardial hypokinesia (one 
patient) and psychosis (two patients). This regimen can only be justilied if the 
therapeutic results are superb, which has yet to be awaited. 
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Introduction. 
Interleukin-2 (IL2) and interferon-alpha (IFNe<) are biologic substances 
involved in the regulation of the immune system. The administration of IL2 or 
IFNe< can mediate tumor regression in patients with metastatic melanoma (1-7). 
The mechanisms by which IL2 and IFNe< mediate antitumor effects are different. 
IL2 has the ability to expand and activate subpopulations of cytotoxic T cells, NK-
and K cells (8-10). Administration of IL2 can also stimulate the antitumor 
reactivity of adoptively transferred IL2 activated lymphocytes (LAK) (1). IFNe< 
exerts a variety of other effects such as direct antitumor cytotoxicity, increased 
expression of major histocompatibility class II (MHC) antigens on tumor cells, and 
the potential to stimulate the differentiation of malignant cells (11). There is 
considerable interest in the synergistic effects of IL2 and IFNe< against tumor cells. 
Preclinical studies in animal tumor models showed that the combined administration 
of IL2 and IFNe< mediated greater therapeutic effects against established 
subcutaneous, hepatic and pulmonary metastases than either agent alone (1,12-14). 
In a study with escalating dose levels of both IL2 and IFNe< Rosenberg et al (15) 
have observed response rates as high as 44 % in a group of patients with renal cell 
cancer and melanoma. 
Based upon these observations, we have initiated two studies with different 
doses and schedules of IL2 and IFNe< combination therapy in metastatic melanoma. 
The results of these studies are reported here. 
Patients and methods 
Patients 
From December 1988 to October 1989 58 patients with metastatic melanoma 
were entered in the first phase II trial. Eligibility criteria included: age 18 - 70 
years, Karnofsky performance status 80-100, no metastases in the central nervous 
system, no significant cardiovascular history, serum bilirubin and creatinine within 
normal range, normal bone marrow function (HCT > 30%, WBC > 4000/ml, 
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platelets > 100000/ml), normal coagulation parameters, no previous treatment with 
-- TLz·oiIPNCi,\vashouCpeflodo{·at·feast4-weeks -fofcy(otoiiic"he111otllerapy-and 
negative tests for HIV antibody and hepatitis-B antigen. Pre-treatment 
characteristics are shown in Table 1. Sites of metastatic disease were skin (34 %), 
lymph nodes (66%), liver (29%), lung (31 %) and bone (17%). In the second 
ongoing trial nine patients (six males and three females) with a median age of 47 
years (range 28-60) have presently been entered. Patient characteristics and disease 
sites are comparable to those in the first trial. 
TABLE 1 PATIENT CHARACTERISTICS (FIRST STUDy) 
Age, median (range) 54 (21-72) 
Sex 
female 30 (52%) 
male 28 (48%) 
Karnofsky performance status 
80 15 (26%) 
90 22 (38%) 
100 21 (36%) 
Prior chemotherapy 20 (34%) 
Prior radiotherapy 5 ( 9%) 
Treatment 
In the first study IL2 was given by continuous infusion of 3.0 BRMP 
(Biological Response Modifiers Program) MU/m'/day for 4 days combined with a 
subcutaneous injection of IFN« 6 MU/m'/day on day 1 + 4 followed by a rest 
period of 10 days. 
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The cycle-was·· repeated at day. 15,·Evaluation.· of response was . done-after each. 
four cycles. Patients received 13 cycles of treatment unless progressive disease was 
documented. During treatment other anticancer therapy was prohibited. 
Paracetamol or indomethacine were used to control fever. Vomiting and diarrhea 
were treated symptomatically. Fluid output was carefully monitored and corrected. 
In the second study treatment consisted of three daily i. v. bolus injections of IL2 
4.5 BRMP MUlm' and IFNa 3.0 MUlm' for 5 days followed by a 16 day rest 
period. The intended treatment plan consisted of three cycles after which evaluation 
of response was done. 
Patient monitoring 
Response was evaluated according to WHO guidelines (16). A complete 
response was defined as the disappearance of all known disease (measurable and 
non-measurable) for at least 4 weeks. A partial response was defined as a reduction 
in the sum of the products of the largest perpendicular diameters of each lesion by 
at least 50% for at least 4 weeks. Stable disease denoted less than 50% tumor 
reduction and less than 25 % tumor progression. Progressive disease was defined as 
the appearance of a new lesion or an increase in size of more than 25 % of any 
lesion. Toxicity was recorded and analysed using the WHO grading system (16), if 
possihle, or otherwise a grading system from 1 to 3, in which grade I = mild, 2 
= moderate and 3 = severe toxicity. 
Results 
Response 
a. first stlldy 
54/58 patients were evaluable for response. Two patients were entered, but 
never treated. One suffered a ketoacidotic coma and one refused treatment. One 
patient (2%), who entered the study just before its completion, achieved a complete 
response, for a duration of 4+ weeks. There were 10 (19%) partial responses with 
a mean duration of 19.5+ weeks (range 13-37+ weeks). The overall response rate 
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was 21 % .19 I}atients had stable disease In 24 patients progressive disease 
was documented (44%). Responses were seen in lymph nodes (29%), skin (25%), 
adrenal gland (20%), lung (17%), liver (12%). 
b. second stltdy 
Nine patients received a median of 24 doses (53%) (range 8-41) of the planned 
total of 45 IL2 and IFN", doses. Four patients completed fully all three treatment 
cycles. Treatment was discontinued in one patient after two cycles and in four 
patients after one cycle because of unacceptable toxicity. In four of the live patients 
who received more than one treatment course, IL2 and IFNa doses had to be 
reduced to 50%. Of the nine evaluable patients, one achieved a complete and four 
a partial response (overall 56%), three had stable disease and one progressed. 
Toxicity 
a. first study 
All 58 patients were evaluable for toxicity. The side effects are listed in Table 
2. Fever, chills, anorexia, nausea and diarrhea occurred in most patients. Other 
frequently reported adverse effects were fatigue, muscle pain and headache. 
Erythema was seen in 55 % of patients, desquamation in 48 % and pruritus in 26 %. 
Hypotension was noted in 67% of the patients; in seven patients grade 3 and in two 
grade 4. Weight gain and fluid retention were generally modest and occurred in 
43% of cases. Oliguria was seen in only 10% of patients. Ventricular arrythmia 
developed in three and atrial librillation in two patients. The most frequent 
manifestation of hematological toxicity was anemia (64%). Moderate and reversible 
increases in serum creatinine and bilirubin were seen in 15 % of patients. No toxic 
death occurred and all toxicities resolved after cessation of IL2 and IFNa. 
Hypothyroidism was observed in 10 % of patients. Chronic cumulative fatigue 
occurred after about 3 months of treatment. Consequently no patient did receive 
more than 13 cycles. 
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TABLE 2 ADVERSE EVENTS (FIRST STUDy) 
adverse event number of WHO grading 
patients (%) 1 2 3 4 
fever 58 (100) 30 27 0 
skin rash/erythema 32 (55) 13 18 1 0 
nausea/vomiting 55 (95) 7 37 11 0 
diarrhea 42 (72) 14 21 7 0 
malaise 18 (31) 1 13 4 0 
weight gain 25 (43) 14 10 1 0 
hypotension 39 (67) 12 18 7 2 
tachycardia 21 (36) 5 13 3 0 
dyspnea 8 (14) 2 5 1 0 
creatinine 9 (16) 6 3 0 0 
alkaline phosphatase 52 (90) 31 19 2 0 
anemia 37 (64) 26 11 0 0 
b. second stlldy 
This intensifed treatment schedule was accompanied by considerable toxicity. 
All nine patients suffered from malaise, fever, chills, nausea, vomiting and 
diarrhea. At the end of even the first cycle all patients complained of extreme 
fatigue. Nausea and vomiting were easily controlled by antiemetics, but diarrhea 
was sometimes intractable. Weight gain exceeding 5% of the starting body weight 
was observed in 5/9 patients. Transient hyperbilirubinemia and increased creatinine 
were seen in seven and nine patients, respectively. In every patient increases in 
transaminases (SGOT and SGPT) were observed. In four patients side effects led to 
a dose reduction of 50% in subsequent cycles, intractable diarrhea of several litres 
per day in one patient, hypotension grade 3 and anuria in two patients and 
hyperbilirubinemia > 100 !unolll in one patient. Treatment had to be terminated in 
five patients due to myocardial infarction (one patient), atrial fibrillation (one 
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patient), negative T waves and myocardial hypokinesia (one patient) and psychosis 
. (two patients): . 
Discussion 
Monotherapy with IL2 has resulted in 25 % mostly partial responses in patients 
with metastatic malignant melanoma (5). Response rates of 3-36% have been 
observed in studies utilizing the combination of IL2 and LAK (3,5,6,17). Patients 
treated with IL2 and IFNO! in three different phase I-II studies showed a 21-44% 
response rate (4,7,15). Higher doses of IL2 and IFNO! appeared to correspond with 
a higher response rate (15). 
In the first multicenter phase II study, reported here, antitumor efficacy was 
demonstrated, but the overall response rate of 21 %, including only 2% complete 
response, was disappointingly low. This may have been due to suboptimal dose and 
schedule. 
In an attempt to confirm the results obtained in the NCI escalating dose study 
(15), we have chosen dose level 3 of that particular study; the one but highest 
dose, which had yielded a 44 % overall response rate, despite the fact that the 
toxicity precluded the administration of more than 60% of protocol dose; i.e. 30 
doses of IL2 and IFNO!. We introduced two modifications, a rest period of 2 weeks 
instead of one and a total of three cycles instead of two. Our preliminary results 
showed an encouraging response rate of 56%. The side effects, however, were 
impressive. In five patients grade 3-4 toxicities necessitated the discontinuation of 
further treatment and in four patients dose reductions had to be made. This 
treatment schedule can only be justified if the therapeutic results are superb, which 
has yet to be awaited. 
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Summm'Y 
A multicentre study of IL2 and IFN", was performed in 57 patients with 
metastatic melanoma. The treatment scheme consisted of IL2 7,8 MIU/m'/day as a 
continuous infusion for 4 days combined with subcutaneous administration of IFN", 
6 MIU/m'/day, day I +4. The cycle was repeated every 2 weeks for a maximum 
number of 13 cycles. Further treatment beyond half a year was allowed. Evaluation 
was done after every 4 cycles. 
Fifty-one patients were evaluable for response and toxicity. One (2 %) achieved 
a complete and 7 (14%) a partial response, total response rate 16% (CI 7-29%). 
Twenty patients (39%) were stable and 23 (45%) showed progressive disease. Time 
to progression was 2.5 months for all patients and 8.2 months for the responding 
patients. Median survival of all eligible patients was 11.3 months and of the 
responding patients 20.2 months. Common side effects included fever, chills, 
fatigue, skin rash, anorexia, nausea and diarrhea. 
These results show that this regimen of IL2 and IFN", is only moderately active 
and not superior to IL2 alone. 
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Introduction 
In metastatic melanoma no life-prolonging therapies exist. The best chemo-
therapy available comprises dacarbazine (DTIC) or cisplatin, which yields response 
rates between 5 % and 30%. Response duration is usually very brief and there is no 
survival benefit (1-3). 
Immunotherapy with recombinant interleukin-2 (IL2) has been reported to yield 
a 5-27% response rate in metastatic melanoma (4-11). Early studies of IL2 with 
lymphokine-activated killer cells (LAK) reported high response rates of 30-50% 
(12,13), but other reports showed lower response rates of 3-23% (5,10,14-18). 
Several studies of IL2 combined with a chemotherapeutic agent such as DTIC or 
cyclophosphamide have been carried out and have yielded response rates of about 
25% (19-23). Interferon-alpha (lFNa) has shown response rates of 12-22% 
(24,25). 
Based on the synergistic activity of IL2 and IFNa in preclinical experiments 
(26-28) and on the encouraging results of early clinical trials with this combination 
(29-31), we decided to perform a phase II study. Here, we report the final analysis 
of the treatment results after a median follow-up period of 10.5 months (range 1.1-
47 + months). 
Material and methods 
Patients 
Fifty-seven patients were entered in the study. The protocol required histologic 
or cytologic documentation of metastatic melanoma and measurable, progressive 
metastatic disease. Eligibility criteria included: age 18-70 years, Karnofsky 
performance status 60-100, no metastases in the central nervous system, no 
signiticant cardiovascular history, normal pulmonary function, serum bilirubin and 
creatinine within normal range, normal bone marrow function (HCT > 30%, 
WBC > 4000/ml, platelets> IOOOOO/ml), normal coagulation parameters, normal 
serum calcium and negative tests for HIV antibody and hepatitis-B antigen. 
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.... .._Previ()llstreatment with IL2orII'Na was not allowed. Pri()rradiotherap), or 
chemotherapy had to be completed at least 4 weeks before entry into the study (6 
weeks for nitrosoureas or mitomycin). Any significant disease such as infection or 
peptic ulcer had to be controlled. Corticosteroids were prohibited. 
The protocol was reviewed and approved by the institutional review board and 
the ethical committee of each participating centre. 
Six patients were ineligible; 3 had unmeasurable disease, 2 had brain metasta-
ses, I was pretreated with interferon-2{3. Fifty-one patients were evaluable for 
response and toxicity. The patient characteristics are shown in Table 1. The median 
time from initial diagnosis to immunotherapy was 24 months (range 1 to 142 
months). 
TABLE 1 PATillNT CHARACTERISTICS 
Number of patients 
Age 
Sex 
median 
range 
male 
female 
Performance status (Karnofsky) 
median 
range 
Prior therapy 
none 
chemotherapy 
radiotherapy 
hormone therapy 
32 
51 
49 
21-72 
29 (57%) 
22 (43%) 
90 
70-100 
25 (49%) 
19 (37%) 
5 (10%) 
2 (4%) 
TABLE 1 CONTINUED 
Distribution of metastatic sites 
lung 
lymph nodes 
skin 
liver 
bone 
Number of metastatic sites 
1 
2 
3 
4 
5 
6 
Treatment 
20 
29 
16 
17 
10 
15 
14 
10 
9 
2 
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(39%) 
(57%) 
(31 %) 
(33%) 
(20%) 
(29%) 
(27%) 
(20%) 
(18%) 
(4%) 
(2%) 
Patients were treated with IL2 at a dose of 7,8 MIU/m'/day by continuous 
infusion on days 1-4 and with IFNOI-2a 6 MIU/m'/day by subcutaneous injection on 
day I and 4 of each treatment cycle. IL2 (Teceleukin) and IFNOI (Roferon-A) were 
supplied by Hoffmann-La Roche Ltd, Basle, Switzerland. Cycles were repeated 
every 2 weeks. 
Evaluation of response was performed after 4 cycles and every 2 months 
thereafter. Patients with response and no change received 9 additional treatment 
cycles. Further continuation of treatment beyond half a year was allowed. During 
treatment other anticancer therapy was not allowed. Paracetamol or indomethacine 
were used to control fever. Vomiting and diarrhea were treated symptomatically. 
Fluid output was carefully monitored and corrected with parenteral infusion if 
necessary. 
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Toxicity was recorded and analysed using the WHO grading system (32). In 
case of grade 1 and 2 toxicity treatment was to continue as scheduled. When grade 
3 neurotoxicity or cardiotoxicity occurred, treatment was discontinued permanently 
and the patient was carefully followed until the adverse event resolved. With all 
other grade 3 toxicities (except fever, nausea/vomiting, diarrhea and hypotension) 
treatment was withheld until the toxicity improved to grade 1 or resolved. Resump-
tion of treatment was allowed in the next cycle. Treatment was permanently 
discontinued in case of grade 4 toxicity. 
Response was evaluated according to the WHO guidelines (32). A complete 
response (CR) was defined as the disappearance of all known disease for at least 4 
weeks. A partial response (PR) was defined as a reduction in the sum of the pro-
ducts of the largest perpendicular diameters of the tumor lesions by at least 50 % 
for more than 4 weeks. Stable disease (SD) denoted less than 50% tumor reduction 
and less than 25 % tumor progression. Progressive disease (PD) was defined as the 
appearance of a new lesion or an increase in size of more than 25 % in any lesion. 
Duration of response and stable disease were calculated from the start of treatment 
to the day of disease progression. Time to progression and survival were calculated 
from the start of protocol treatment until the day progressive disease was tirst 
noted. 
Results 
Response 
Of the 51 eligible patients, 24 (47%) received 2-4 treatment cycles, 12 (24%) 
5-8 cycles, 13 (26%) 9-13 cycles, one patient 15 and one patient 16 cycles. Four 
patients were taken off study early; one due to intercurrent illness and 3 due to 
grade 4 toxicity. 
Table 2 shows the treatment results. The oventll response rate was 16% (CI:7-
29%), including 1 CR and 7 PRs. Twenty patients (39%) had stable disease. In 23 
patients (45%) progressive disease IVas documented. Responses were seen in skin 
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lesions (3§J1>J,1 ynlphnode~J27%),Lung{18%)_andliverJI§%Lgfn()teb()ne 
metastases did not respond. Three of the responders were male and 5 were female. 
All responses occurred in the first 3 months of treatment. 
TABLE 2 RESPONSE TO TREATMENT 
Number of patients 
Complete response 
Partial response 
Stable disease 
Progressive disease 
51 
7 
20 
23 
(2%) 
(14%) 
(39%) 
(45%) 
The median duration of response was 8.2 months (range 4.5-39+ months). For 
all 51 patients the median time to progression was 2.5 months (range 0.5-39+ 
months) [Figure 1]. Time to progression for responding patients was 8.2 months 
(range 4.5-39+ months), for the patients with stable disease 3.6 months (range 
1. 7-9.4 months) and for progressive disease patients 1.2 months (range 0,5-2.0 
months). The median survival of all 51 patients was 11.3 months [Figure 2], and of 
the responding patients 20.2 months. 
Toxicity 
An overview of the observed toxicity in the 51 patients is presented in Table 3. 
Frequently occurring side effects were fever, skin rash, nausea, vomiting, diarrhea 
and malaise. Two-thirds of patients had tachycardia and hypotension, mostly of 
mild to moderate grade. Life-threatening hypotension requiring vasopressors 
occurred in 3 patients, who were taken off study (see above). One patient develo-
ped ventricular extra systoles and another patient atrial fibrillation. In a minority of 
patients neurological ahnormalities and mental disturbances were seen. Neurotoxici-
ty included aphasia, peripheral neuropathy, somnolence, confilsion and agitation. 
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.. .. __ TWQ.p-~ti~'-'1t~Leqlli!~d_<lQs_e[e<luctL()nslJec-"llseoL.adverse .. events.and in 8. 
patients interruption of treatment was needed. No toxic death occurred and all 
toxicities resolved after cessation of IL2 and IFNa. Chronic cumulative fatigue 
occurred after about 3 months of treatment. Consequently only 2 patients did 
receive more than 13 cycles. 
TABLE 3 ADVERSE EVENTS 
Adverse events Number of WHO grading 
patients (%) 1 2 3 4 
Fever 51 (100) 0 21 30 0 
Skin rash/erythema 36 (71) 13 19 4 0 
Nausea/vomiting 48 (94) 7 28 13 0 
Diarrhea 38 (75) 10 20 8 0 
Malaise 29 (57) 4 15 10 0 
Weight gain 15 (30) 13 2 0 0 
Hypotension 39 (76) 7 18 11 3 
Tachycardia 36 (71) 13 20 3 0 
Dyspnea 10 (20) 4 4 2 0 
Mental disturbances 8 (16) 5 3 0 0 
Creatinine 19 (37) 16 3 0 0 
Alkaline phosphatase 30 (59) 12 15 3 0 
Bilirubin 9 (18) 7 2 0 0 
Anemia 36 (71) 17 14 5 0 
Thrombocytopenia 9 (18) 7 2 0 0 
The most frequent manifestation of hematologic toxicity was anemia (71 %). 
Thrombocytopenia was seen in 18% of the patients. Moderate and reversible 
increases in serum creatinine and bilirubin occurred in a minority of patients. 
A remarkable observation was the occurrence of thyroid function abnormalities 
in 18 patients (35%). An increase of serum thyroxine (T4) levels with a concomit-
tant decrease in thyrotropin (TSH) was seen in 10 patients (20%). Low T, levels 
37 
Chapter III 
with high TSH wer,,()~s_er\,ed in 12 eatientsj2~%L'freatlnent\"ithlevothyroxine 
for overt hypothyroidism was needed in 7 patients. Thyroid function abnormalities 
normalized after discontinuation of immunotherapy. 
Discussion 
In this study the combined use IL2 and IFN", in the treatment of metastatic 
melanoma resulted in a 16% response rate, including 2% complete responses. The 
responses occurred in patients with lymph node, lung and skin metastases. The 
median time to progression was approximately 3 months for the whole group of 
patients and 8 months for the responding patients. The median survival of all 
eligible patients was 11 months and of the responding patients 20 months. These 
results are disappointing and not better than can be expected of conventional 
chemotherapy. 
The possible synergistic effects of IL2 and IFN", have led several investigators 
to study the effect of combined treatment with both cytokines. Response rates of 
21-44% have been reported (29,30,33). However, low response rates of 10% or 
less were observed by others (11,18,34,35). In several studies the median response 
duration varied between 2 and 11 months, and the median survival was approxima-
tely 10 months (11,18,29,30,34). We achieved similar results. 
We failed to confirm the ability of IFN", to augment the effect of IL2. This 
may have been due to suboptimal dose and schedule. Patients received moderate 
doses of IL2. In animal studies the efficacy of IL2 is dose dependent without 
reaching a plateau below the maximum tolerated dose (36). However, in trials 
using high-dose IL2 (18 MIU/m'Jday) given by continuous infusion in patients with 
metastatic melanoma inferior response rates were reported (18,34). An NCI 
Surgery Branch Study, administering high-dose bolus IL2 (> 30 MIU/m'Jday) and 
IFN", found the highest response rates (29). On the other hand the Extramural IL2 
Working Group (ILWG), using identical dose schedule and patient selection criteria 
did not observe any evidence of enhanced response with the IL2JIFN", combination 
(I I). In an other ILWG study an inferior response rate and duration was demon-
strated for patients with advanced renal cell carcinoma treated with high-dose IL2 
plus IFN", compared with IL2 alone (37). In summary, a dose-response effect for 
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Another reason for the low results of the present study may be patient selecti-
on. In general the characteristics of our study population are comparable with other 
trials. However, a considerable number of patients had bone metastases and it has 
been suggested that bone metastasis respond poorly to immunotherapy (37-39). 
The side effects, we observed, were of similar incidence and severity as in 
other studies with the combined use of IL2 and IFN", (11,29,30,33-35). Toxicity 
was manageable and patients tolerated the therapeutic regimen relatively well. 
However, cumulative fatigue made it impossible to give patients more than 13 
cycles of therapy. Infectious complications are frequently encountered in IL2 based 
immunotherapy (40). We observed only one infection problem in our patient group. 
This may be related to the fact that we have not used central venous lines routine-
ly. A remarkable observation was the considerable high incidence of thyroid 
function abnormalities. The thyroid dystimction may be the result of an immuno-
therapy induced thyroiditis (41,42,43). 
In conclusion, the combined therapy with IL2 and IFN", in the described 
regimen has only moderate activity in the treatment of patients with metastatic 
melanoma. Further clinical trials have to be designed to improve therapeutic 
results. Recently a decrescendo interleukin-2 dosing schedule has been developed 
with an encouraging response rate and reduced toxicity (44). New reports have 
shown promise for the use of combined or sequential chemo-and immunotherapy 
(45-47). 
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Chapter IV 
Summary 
--------------.----------------.-- -,---
Background: Immunotherapy with interleukin-2 (IL2) and interferon-alpha 
(IFNOI) is moderately active against metastatic melanoma. 
Purpose: This study was undertaken in an attempt to increase the activity by 
high dose bolus administration of IL2 and IFNOI. 
Methods: In the first part of tlle study patients with metastatic melanoma were 
planned to receive IL2 11,7 MID/m' i.v. plus IFNOI 3 MID/m' i.v. by bolus 
administration every 8 hours on days 1-5, to be repeated every 21 days for a total 
of 3 courses. Due to unacceptable toxicity only 18 patients were entered. In the 
second part, the treatment scheme was modified and the patients were treated with 
the same dosages of cytokines, however for 3 instead of 5 days per cycle. 
Results: In the 5-day schedule 17 patients were evaluable for response and 
toxicity. Two (12%) complete responses and 5 (29%) partial responses were 
achieved for an overall response rate of 41 % (95% confidence interval 18-67%). 
The median duration of response was 8.6 months. The study was prematurely 
discontinued because of severe cardiotoxicity in 7 patients (41 %) and central 
nervous system toxicity in 5 patients (28%). Twenty-five patients were treated 
according to the 3-day schedule. Five partial responses were achieved (20%; 95% 
confidence interval 7-43%) with a median duration of response of 6.6 months. 
Toxicity was manageable. 
Conclusion: The high dose 5-day schedule of IL2 and IFNOI yielded a relati-
vely high response rate at the expense of undesirable toxicity. The modified 3-day 
regimen was associated with a response rate of 20%, what was within the 10-25% 
range, expected of conventional IL2 and IFNOI schedules. 
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Introduction 
During the past decade two biological agents, interferon-alpha (IFNa) and 
interleukin-2 (IL2) have shown evidence of activity against metastatic melanoma. 
Interferon-alpha produced objective tumor regression in approximately 15% of the 
patients with advanced disease (1-3). Interleukin-2, with or without lymphokine-
activated killer cells, yielded response rates from 10-25% (4-7). Experiments in 
murine models showed synergism between IL2 and IFNa (8-10). This observation 
has led to a number of clinical studies with the combination of these cytokines. The 
reported response rates varied between 0-44% (11-16). A phase I-II study with 
increasing dose levels of bolus IL2 and IFNa conducted at the US National Cancer 
Institute (NCI) produced an objective response in 33% of patients with metastatic 
melanoma. The highest response rate of 44 % was reached with a schedule of IL2 
II. 7 MIUlm' and IFNa 3 MIUlm' 3 times a day by intravenous bolus administ-
ration, 5 days per cycle (II). We performed a phase II study with this schedule in 
order to confirm these results. 
Patients and methods 
Patient popUlation 
The study was divided into two parts. Due to the occurrence of severe toxicity 
the 5-day regimen was replaced by a 3-day schedule. All patients had histologically 
confirmed melanoma and measurable, progressive metastatic disease. Eligibility 
criteria included: life expectancy of at least 12 weeks, Karnofsky performance 
status of at least SO, age between IS-70 years, no prior immunotherapy with IL2 
and IFNa, no metastases in the central nervous system, no cardiovascular history, 
normal pulmonary function, serum creatinine :;; 1.25 times the upper limit of 
normal, or creatinine clearance "' 50 ml/min, leucocyte count "' 4.0 x 10'/1, 
platelet count "' 100 x 1O'1l, hemoglobin "' 9.5 giIOO ml, and normal liver 
function with the exception of liver function disturbances due to metastatic disease. 
Patients were also excluded in case of active infection, use of systemic corticoste-
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r"ids or positive tests for HIVantibodyo~hep~titis:Bantigen'l'elnal"Piltients()f 
child-bearing age were required to have a negative pregnancy test. All patients 
gave informed consent. 
Treatment 
In part I of the study patients received recombinant IL2 at a dose of 11.7 
MIU/m2 (Teceleukin; Hoffman La Roche, Nutley, NJ) and recombinant IFNa at a 
dose of 3 MIU/m' (Roferon-A, Hoffman La Roche, Basle, CH), each administered 
as an intravenous injection over 15 minutes, every 8 hours on days 1-5. This 5-day 
cycle was repeated every 21 days up to a total of 3 cycles. The cytokines were 
given via a tunneled central venous double lumen catheter. With this schedule we 
were confronted with severe and life-threatening cardiotoxicity, albeit that the first 
3 days of treatment were relatively well tolerated. Therefore, we decided to modify 
the treatment schedule, using the same daily dosages ofIL2 and IFNa, but now for 
3 instead of 5 days. 
Patients were treated and monitored on the clinical ward with frequent 
assessments of vital signs, weight, and fluid balance. Hematologic and biochemical 
blood tests were performed on days 1,3, and 5 of each treatment cycle. A 12-lead 
ECG was obtained daily during therapy. Acetaminophen 500 mg orally every 4 
hours was given to control fever. Nausea and vomiting were treated with alizapride 
150 mg Lv. every 4 hours. In addition, pethidine for chills, loperamide for 
diarrhea, terfenadine for pruritis and pipamperon for mental confusion were given 
if indicated. Corticosteroid administration was not allowed, except in the event of 
life-threatening toxicity. Patients with weight loss secondary to vomiting or 
diarrhea were given supplementary Lv. fluids. 
The World Health Organization (WHO) criteria were used to grade toxicity 
(17). Treatment was permanently discontinued if grade 3 neurotoxicity or cardio-
vascular toxicity occurred. In case of grade 3 hypotension, therapy was continued 
while giving symptomatic treatment with colloids. If volume expansion gave no 
improvement, dopamine was added (maximum dose of 5 "g/kg/min). Treatment 
was discontinued if the patient remained hypotensive and/or oliguric (urine 
production < 80 mIlS hours). In all other cases of grade 3 toxicity with the 
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exception of fever, nausea/vomiting and diarrhea, immunotherapy was discontinued 
-- -- -- -- -- - - -- - - - - --- ---- --- --- - - -- -- ---- -- --- --- -- --- ----- -- - -- -- --- ------
until toxicity improved to grade 1 or resolved. Resumption of treatment at 50 % of 
the previous dose was allowed in the next cycle if grade 3 toxicity decreased to 
grade 1 or less. 
Response assessment 
The first tumor assessment was performed at 8 weeks after the start of therapy. 
Response evaluations were repeated every 4 weeks. Tumor response categories 
were defined according to WHO criteria (17). A complete response (CR) was 
de tined as the disappearance of all known disease for at least 4 weeks, a partial 
response (PR) as a reduction in the sum of the products of the 2 largest perpendicu-
lar diameters of all lesions by at least 50% for more than 4 weeks, without the 
appearance of any new lesion. Stable disease (SD) denoted less than 50% tumor 
reduction and less than 25 % tumor progression. Progressive disease (PD) was 
defined as the appearance of a new lesion or an increase in size of more than 25 % 
in any indicator lesion. The treatment results were analyzed on an intent -to-treat 
basis. The confidence interval of the observed response rate was computed using 
the exact binomial distribution. Duration of response, time to progression and 
survival were calculated from the start of treatment. The median survival was 
estimated using the Kaplan-Meier method. 
Immullologicalmollitoring 
Absolute numbers of lymphocyte subsets and cytotoxic activities of peripheral 
blood mononuclear cells (PBMC) were assessed in each treatment cycle, immedia-
tely prior to the first administration of IL2 and IFN", and one week later. The 
PBMC were isolated by Ficoll-Isopaque density centrifugation of heparinized 
venous blood samples. An aliquot was processed immediately for immunopheno-
typing. The remainder was cryopreserved in liquid N, so that all samples from a 
given patient were tested for cytotoxicity at one occasion to exclude interassay 
variability. The lymphocyte subsets defined by double-staining with CD3 and 
CD56, CD4 and CD8, CDI6 and CDl9 monoclonal antibodies were assessed by 
multicolor immunofluorescence and flow cytometry as described elsewhere (18,19). 
Cytotoxic activities of lymphocytes were determined in standard 3-h SlCr-release 
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assays as described_previously (18).TheK562erythromy~loidleuk_en~iaceIIline 
and the Daudi Burkitt's lymphoma cell line were used as target cells for the assess-
ment of natural killer (NK) and lymphokine-activated killer (LAK) activities, 
respectively. 
Results 
Patient characteristics 
Forty-three patients were entered in the study, 18 in part I and 25 in part II. 
The patient characteristics are summarized in Table 1. All eligible patients were 
evaluable for response and toxicity. In the 5-day regimen, one patient was ineligi-
ble because of unmeasurable disease. Two patients had previously been treated with 
isolated limb perfusion with melphalan and one patient received palliative radiothe-
rapy before study entry. In the 3-day regimen, 2 patients were pretreated with 
adjuvant BCG or Poly A-Poly U immunotherapy. The other patient characteristics 
were similar for both parts of the study. 
TABLE 1 PATIENT CHARACTERISTICS 
Part I Part II 
Evaluable patients 17 25 
Age 
median 48 41 
range 29-61 20-69 
Sex 
male 9 (53%) 16 (64%) 
female 8 (47%) 9 (36%) 
Performance status (Karnofsky) 
median 90 90 
range 80-100 80-100 
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TABLE 1 CONTINUED 
Prior therapy 
surgery 17 (100%) 25 (100%) 
immunotherapy 0 2 (8%) 
chemotherapy 2 (12%) 0 
radiotherapy 1 (6%) 0 
Distribution of metastatic sites 
lung 9 (53%) 10 (40%) 
lymph nodes 7 (41 %) 17 (68%) 
subcutaneous 6 (35%) 12 (48%) 
liver 6 (35%) 9 (36%) 
other (adrenal, pancreas, bone) 8 (47%) 9 (36%) 
Number of metastatic sites 
1 6 (35%) 7 (28%) 
2 4 (24%) 7 (28%) 
3 4 (24%) 7 (28%) 
4 2 (12%) 4 (16%) 
5 1 (6%) 0 
Treatment characteristics 
Of the 17 evaluable patients in part I, 9 (53%) received 3 treatment cycles, 3 
(18%) 2 cycles and 5 (29%) only 1 cycle. Eight patients were taken off study 
early; 6 due to grade 3-4 toxicity, one due to rapidly progressive disease and 
another patient refused further treatment. The actual cytokine doses given during 
the first, the second and the third cycle, expressed as percentage of the planned 
dose were 85%, 42% and 30%, respectively. 
Of the 25 evaluable patients in part II, 14 (56%) received 3 cycles, 5 (20%) 2 
cycles and 6 (24 %) one cycle. The actual cytokine doses administered to these 
groups of patients were 95%, 71 % and 54% of the planned dosages, respectively. 
Treatment was discontinued in one patient after only one single cytokine infusion 
due to the development of grade 3 toxicity. He was considered a treatment failure. 
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Treatment results 
Table 2 shows the results of response and survival. With the 5-day schedule the 
overall response rate was 41 % (95% confidence interval 18-67%), including 2 
CRs. The overall survival was 10.2 months (range 2.6-37.5 months). The respon-
ding patients had a median survival of 27.4 months (range 2.7-37.5 months). With 
the 3-day schedule the overall response rate was 20 % (95 % confidence interval 7-
43%). No complete responses occurred. The overall survival was 6.8 months 
(range 0.9-24+ months). The responding patients had a median survival of 14.2 
months (range 6.6-21.5 months). 
TABLE 2 RESPONSE TO TREATMENT 
Part I Part II 
Evaluable patients 17 25 
Complete response (CR) 2 (12%) 0 
Partial response (PR) 5 (29%) 5 (20%) 
Overall response rate 41 % 20% 
Stable disease (SD) 3 (18%) 4 (16%) 
Progressive disease (PD) 7 (41 %) 16 (64%) 
Median duration of response 8.6 months 6.6 months 
(range) (2.0-37.5) (3.9-9.9) 
Median time to progression 3.2 months 2.0 months 
(range) (0.7-37.5) (0.5-9.9) 
Median survival 10.2 months 6.8 months 
(range) (2.6-37.5) (0.9-24+) 
Toxicity 
Adverse effects are shown in Table 3. Fever, fatigue, nausea, vomltmg and 
diarrhea were frequently observed. With the 5-day schedule a high incidence of 
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severe cardiac toxicity occurred. Seven patients (41 %) experienced cardiac adverse 
events; cardiomyopathy in 4, acute cardiac arrest, myocardial infarction and 
negative T-waves on the ECG in one patient each. The details of these patients 
have been reported elsewhere (20). No cardiotoxicity was observed in the 3-day 
regimen. 
Two-thirds of patients in the 5-day regimen suffered from neuropsychiatric dis-
turbances such as agitation, disorientation, confusion and overt psychosis. With the 
3-day regimen neuropsychiatric side effects were encountered in about one-third of 
patients, and were mild in most cases. Neurotoxicity completely resolved in all 
patients. 
TABLE 3 ADVERSE EVENTS 
Part I Part II 
Adverse events (%) Grade 1/2 Grade 3/4 Grade 112 Grade 3/4 
Fever 12% 88% 52% 48% 
Skin rash 76% 0% 64% 0% 
Nausea/vomiting 76% 18% 40% 52% 
Diarrhea 53% 35% 48% 44% 
Malaise 24% 76% 40% 56% 
Weight gain 35% 0% 16% 4% 
Hypotension 41 % 53% 60% 32% 
Cardiac 6% 35% 0% 0% 
Dyspnea 53% 24% 28% 8% 
Neuropsychiatric 41 % 29% 32% 4% 
Oliguria 18% 18% 20% 12% 
Creatinine 47% 0% 12% 0% 
Alkaline phosphatase 76% 6% 56% 4% 
Bilirubin 47% 12% 16% 12% 
Transaminases 47% 53% 60% 24% 
Anemia 53% 0% 36% 8% 
Thrombocytopenia 41 % 6% 48% 0% 
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Immunologic monitoring 
-- -- --- -- ---- ---- -
Prior to therapy the absolute numbers of NK lymphocytes [CD56+ 3- and 
CD16+], T lymphocytes [CD3+], helper/inducer T lymphocytes [CD4+], cyto-
toxic/suppressor T lymphocytes [CD8+j and B lymphocytes [CD19+j were within 
the normal range. During therapy, the CD56+ 3-, CD3+ and CD8+ lymphocyte 
counts gradually increased above normal, whilst the CD4+ and CD19+ remained 
within the normal range (Figure 1). The number of lymphocytes after each 
treatment cycle (rebound lymphocytosis) reached a higher value in the 5-day study 
(Figure 1, open symbols) compared to the 3-day study (closed symbols). NK and 
LAK cytotoxic activities of PBMC remained within the normal range in both parts 
of the study, with a large variation between patients (data not shown). There was 
no relationship between tumor response and immune parameters. 
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Figure 1. Median absolute numbers of CD56+ ,3" (upper left pannel). CD3+ (upper right panne!), CD4 + (lo\ver 
left pannel) and CD8+ (lower right pannel) lymphocytes in patients treated in the 5-day schedule (open symbols) 
and in the 3-day schedule (closed symbols). Logarithmic scales have been used for the vertical axes in order 10 
compress the figure. Vertical bars represent confidence limits as defined by the 5th and 95th percentile of each 
group. The areas between the horizontal lines represent the normal range of the different lymphocyte subsets as 
detlned by the 5th and 95th percentiles of healthy control persons. 
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Discussion 
From an earlier carried out NCI dose escalating study of bolus IL2 and IFNi> 
we selected the dosage schedule with the highest response rate in patients with 
metastatic melanoma (IL2: 11.7 MIU/m' and IFNi>: 3 MIU/m', 3 times a day, 
during 5 days). This treatment schedule resulted in a 41 % response rate (95% CI 
18-67%), which is identical to the results reported by the NCI investigators (II). 
However, we observed a high incidence of severe cardiotoxicity. Light-and 
electronmicroscopic examination revealed cardiomyopathy and myocarditis (20). 
Although severe myocardial toxicity was not so frequently encountered in the NCI 
study as we did, several cases of myocardial infarction and elevation of cardiac 
enzyme levels in 15% of treatment courses were reported (11, 21). Also other 
recent literature indicates that high-dose IL2 regimens bear a high risk of severe 
cardiotoxicity (22-24). 
The second severe toxicity of this 5-day regimen consisted of severe neuropsy-
chiatric disturbances. Evidence from earlier studies showed that the frequency and 
severity of these side effects are dose dependent (12,13,15,23,25-28). The NCI 
investigators observed severe neurotoxicity including coma in 54% of patients (21). 
Thus, these promising results on response were accompanied by unacceptable 
toxicities. In an attempt to maintain the high antitumor activity and to reduce the 
side effects, we shortened in the second part of the study the treatment duration 
from 5 to 3 days. Indeed, the 3-day schedule was accompanied with acceptable 
toxicity, but the response rate dropped to 20%. A direct comparison between the 
two schedules is difficult, because it was not a randomized study and the confid~n­
ce intervals showed considerable overlap. The response rate and survival duration 
of the 3-day schedule were in the same range as observed in most other reported 
studies of IL2 and IFNi> in melanoma (12-14,16,21,27,29). In a recent progress 
report the NCI investigators observed a similar decrease in treatment results after 
modification of the treatment schedule (I instead of 3 IFNi> administrations per 
day), made necessary by the encountered toxicity (21). In general, the response 
rates and survival data of combined therapy with ILl and IFNi> in patients with 
metastatic melanoma appeared not to be superior to treatment with IL2 alone or 
IL2 in combination with lymphokine-activated killer cells (13,21,30-34). 
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With to the evaluated immune parameters\veobserved some difference 
in the degree of lymphocytosis between the 5-day and the 3-day regimen, but there 
was no association between lymphocyte counts, phenotypic changes or cytotoxic 
activity of lymphocytes and tumor response. This lack of relationship is also 
reported by others (35-37). It appears that the quantification of these general 
parameters gives insight into the degree of immune modulation achieved with a 
particular treatment rather than in the mechanism of its therapeutic effect. 
In summary, the combination of IL2 and IFNa has not meaningfully improved 
the clinical results that may be obtained with IL2 alone. Because of the disappoin-
ting treatment results with cytokines alone in metastatic melanoma and because of 
the reported possibility of additive or synergistic effects between chemotherapy and 
cytokines (38-41), we participate at this moment in a phase III study of the EORTC 
Melanoma Cooperative Group, comparing the combination of IFNa, cisplatin and 
dacarbazine with or without IL2. 
54 
Chapter IV 
References 
1. Robinson WA, Mughal TI, Thomas MR et al: Treatment of metastatic malignant 
melanoma with recombinant interferon-alpha-2. Illununobiol 1986;172:275-282. 
2. Creagan ET, Schaid DJ, Ahmann DL et al: Disseminated malignant melanoma and 
recombinant interferon: analysis of seven consecutive phase II investigations. J Invest 
Dennatol 1990;95:188S-192S. 
3. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oneal 
1991;18(suppI7):83-89. 
4. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 
patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 
or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897. 
5. Rosenberg SA, Lotze MT, Yang JC et al: Experience with the use of high-dose 
Interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485. 
6. Parkinson DR, Abrams JS, Wiernik PH et al: Interleukin-2 therapy in patients with 
metastatic malignant melanoma: A phase II study. J Clin Oncol 1990;8:1650-1656. 
7. Whitehead RP, Kopecky KJ, Samson MK et al: Phase II study of intravenous bolus 
recombinant interleukin-2 in advanced malignant melanoma, J Natl Cancer Inst 
1991 ;83: 1250-1252. 
8. Brunda MJ, Bellantoni D, Sulich V: In vivo antitumor activity of combinations of 
interferon-lX and interleukin-2 in a murine model. Correlation of efficacy with the 
induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987;40:365-
371. 
9, Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combi-
nation immunotherapy with recombinant interleukin-2 and a recombinant hybrid lX-
interferon in the treatment of established murine hepatic metastases. Cancer Res 
1988;48:5810-5817. 
to, ligo M, Sakurai J, Tamura T et al: In vivo antitumor activity of multiple injections of 
recomoinant interleukin-2 alone and in combination with three different types of 
recombinant interferon on various syngeneic murine tumors. Cancer Res 
1988;48:260-264. 
II. Rosenberg SA, Lotze MT, Yang JC et al: Combination therapy with interleukin-2 and 
lX-interferon for the treatment of patients with advanced cancer. J Clin Oneal 
1989;7: 1863-1874. 
12. Dillman RO, Church C, Oldham RK et al: Inpatient continuous-infusion interleukin-2 
in 788 patients with cancer. The national biotherapy study group experitmce. Cancer 
1993;71 :2358-2370. 
13. Sparano JA, Fisher IU, Sunderland M et al: Randomized phase III trial of treatment 
with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in 
patients with advanced melanoma. J Clin Oncol 1993;11:1969-1977. 
14. Whitehead RP, Figlin R, Citron ML et al: A phase II trial of concomitant human 
interleukin-2 and interferon-a-2a in patients with disseminated malignant melanoma. J 
Immunother 1993;13:117-121. 
55 
Chapter IV 
15. Keilholz U, Scheibenbogen C, Tilgen W et al: Interferon-a and interleukin-2 in the 
... ..... .... ........ tre'[ttmeIit --, 'of ---'mefaslatic --rii'e lanohi[i':'-'--- Cb'riiparis'oii"'-'-of----f\;v6 '--'phil'se' ----lr -trials-: '" --, Ciiricer 
1993;72:607-614. 
16. Kruit WHJ, Goey SH, Calabresi F et al: Final report of a phase II study of 
interleukin-2 and interferon-a in patients with metastatic melanoma. Br J Cancer 
1995;71: 1319-1321. 
17. WHO handbook for reporting results of cancer treatment. Geneva 1979. 
18. Gratama JW, Bruin RJ, Lamers CHJ et al: Activation of the immune system of 
cancer patients by continuous i. v. recombinant interleukin~2 (rIL2) therapy is 
dependent of dose and schedule of rIL2. Clin Exp Immunol 92:1993;185-193. 
19. Gratama JW, Schmitz PIM, Goey SH et al: Modulation of immune parameters in pa-
tients with metastatic renal cell cancer receiving combination inUllunotherapy (lL-2, 
IFNa and autologous IL-2-activated lymphocytes). Int J Canc 1996;65: 152-160. 
20. Kruit WHJ, Punt CJA, Goey SH et al: Cardiotoxicity as a dose-limiting factor in a 
schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. Cancer 
1994;74: 1850-1856. 
21. Marincola FM, White DE, Wise AP et al: Combination therapy with interferon alfa-
2a and interleukin-2 for the treatment of metastatic cancer. J Clio Oneal 
1995; 13: 111O-1122. 
22. Sznol M, Clark JW, Smith JW et al: Pilot study of interleukin-2 and lymphokine-
activated killer cells combined with immunomodulatory doses of chemotherapy and 
sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell 
carcinoma. J Nat! Cancer Inst 1992;84:929-937. 
23. Atkins MB, Sparano J, Fisher RI et al: Randomized phase II trial of high-dose 
interleukin-2 either alone Of in combination with interferon alfa-2b in advanced renal 
cell carcinoma. J Clin OncoI1993;1l:661-670. 
24. Fossa SD, Aune H, Baggerud E et al: Continuous intravenous interleukin-2 infusion 
and subcutaneous interferon-a in metastatic renal cell carcinoma, Eur J Cancer 
1993;29A; 1313-1315. 
25. Adams F, Quesada JR, Gutterman JU: Neuropsychiatric manifestations of human 
leukocyte interferon therapy in patients with cancer. JAM A 1984;252:938-941. 
26. Denicoff KD, Rubinow DR, Papa MZ et al: The neuropsychiatric effects of treatment 
with interleukin-2 and Iymphokine activated killer cells. Ann Intern Med 1987;107:-
293-300. 
27. Atzpodien J, Korfer A, Franks CR et al: Home therapy with recombinant interleukin-
2 and interferon-a2b in advanced human malignancies. Lancet 1990;335: 1509-1512. 
28. Siegel JP and Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704. 
29. Bergmann L, Weidmann E, Mitrou PS et al: Interleukin-2 in combination with 
interferon-alpha in disseminated malignant melanoma and advanced renal cell 
carcinoma, a phase 1111 study. Onkologie 1990; 13: 137-140. 
30. Dutcher JP, Creekmore SO, Weiss GR et al: A phase II study of interleukin-2 and 
Iymphokine-activated killer cells in patients with metastatic malignant melanoma. J 
Clin Oncol 1989;7:477-485. 
56 
Chapter IV 
31.,B,ar ,MI:I., Sznol,,11, Atkins MBet al: Metastaticlualignant "mcIanoma treated with 
- -- - cOIllbined -b-olus and --c-ontinUQU8 -fnfusfon -interleuidn-2 and -iyrilphokine--aciLvatect---kHIer-----
cells. J Clin Oncol I990;8:1138·1147. 
32. Dutcher JP, Gaynor ER, Boldt DH et aI: A phase II study of high·dose continuous 
infusion interleukin·2 with Iymphokine·activated kiner cells in patients with metastatic 
melanoma. J Clin Oncol 199I;9:641-648. 
33. Rosenberg SA, Lotze MT, Yang JC et al: Prospective randomized trial of high·dose 
interleukin·2 alone or in conjunction with Iymphokine·activated kiner cells for the 
treatment of patients with advanced cancer J NaH Cancer Inst 1992;85:622·632. 
34. Rosenberg SA, Yang JC, Topalian SL et al: Treatment of 283 consecutive patients 
with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. 
JAMA 1994;271:907·913. 
35. Sondel PM, Kohler PC, Hank JA et al: Clinical and innnunological effects of 
recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. 
Cancer Res 1988;48:2561·2567. 
36. Hermann GG, Geertsen PF, Von del' Maase H et al: Interleukin·2 dose, blood 
monocyte and CD25 + lymphocyte counts as predictors of clinical response to 
interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immuno-
ther 1991;34:111·114. 
37. Farace F, Pallardy M, Angevin E et al: Metaslatic renal·cell carcinoma patienls 
treated with interleukin-2 or interleukin-2 plus interferon ')': immunological monito-
ring. Inl J Cancer 1994;57:814·821. 
38. Richards JM, Mehla N, Rannning K el al: Sequenlial chemoimmunolherapy in Ihe 
Irealment of melaslalie melanoma. J Clin Oneol 1992; 10: 1338·1343. 
39. Flaherly LE, Robinson W, Redman BG el al: A phase II sludy of dacarbazine and 
cisplatin in combination with outpatient administered interleukin-2 in metastatic malig-
nanl melanoma. Cancer 1993;71:3520·3525. 
40. Khayal D, Borel C, Tourani JM el al: Sequential chemoimmunolherapy with 
cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oneol 
1993; 11:2173-2180. 
41. Legha SS and Buzaid AC: Role of recombinanl inlerleukin·2 in combinalion with 
interferon-alfa and chemotherapy in the treatment of advanced melanoma. Sem Oneol 
1993 ;20(suppl):27·32. 
57 

Chapter V 
High-dose regimen of interleukin-2 (IL2) and 
interferon-alpha (IFNcx) in combination with 
lymphokine-activated killer cells (LAK) in patients 
with metastatic renal cell cancer 
W.H.J. Kruit, S.H. Goey, C.H.J. Lamers, J.W. Gratama, B. Visser, 
P.l.M. Sclm1itz, A.M.M. Eggermont, R.L.H. Bolhuis, G. Stater 
Chapter V 
Background: Immunotherapy with interleukin-2 (IL2) alone, IL2 and 
lymphokine-activated killer cells (LAK) or IL2 and interferon-alpha (IFN",) has 
resulted in significant antitumor effects in patients with metastatic renal cell cancer. 
Purpose: This study was carried out to investigate if the combined use of all 
three components (IL2, IFN", and LAK) could improve the treatment results. 
Methods: Seventy-two patients with metastatic renal cell cancer were treated. 
Seventeen patients were entered in a feasibility part of the study (protocol I) and 
55 in an efficacy part (protocol 2). Protocol 2 differed from protocol 1 by the 
addition of IFN", to the first 5 days of IL2 infusion. Each patient was planned to 
receive two induction cycles. IL2 18 MIU/m2/day was administered continuous i.v. 
days 1-5 and IFN", 5 MIU/m'/day (protocol 2) i.m. days 1-5, followed by 3 daily 
Iymphaphereses on days 7-9. On day 12 treatment was resumed with IL2 and IFN", 
on days 12-15 and LAK reinfusions on days 12-14. Patients, whose disease 
stabilized or responded, received maintenance therapy with the same dose regimen 
of IL2 and IFNO/ during 4 days every 4 weeks up to a total of 4 cycles. 
Results: In protocol 1, all 17 patients were evaluable. Three complete (CR) 
and one partial (PR) responses were achieved (response rate 24%). The median 
duration of response was 18.1 months. The median survival of the 17 patients was 
13.9 months. The 3-year survival was 35%. Toxicity was manageable and no dose 
reductions were necessary. 
Of the 51 evaluable patients in protocol 2, 6 achieved a CR and 13 a PR 
(response rate 37 %). The median duration of response was 11.1 months. The 
median survival was 16.9 months. The 3-year survival was 35%. There were 3 
treatment related deaths. Other severe toxicities included hypotension, 
cardiotoxicity, pulmonary edema, renal toxicity and infectious complications. In the 
2 induction cycles only 54 % and 42 % of the planned doses of IL2 and IFN", could 
be administered. 
Conclusion: Based on our experience with this treatment schedule of IL2, 
IFN", and LAK we conclude that the use of high-dose regimens with these 
cytokines is not warranted, unless we can accurately define the 25-35% of patients 
who will experience long-term survival as a result of this treatment. 
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Introduction 
High-dose interleukin-2 (lL2) alone or combined with Iymphokine-activated 
killer (LAK) cells leads to a response in 15-30% of patients with metastatic renal 
cell cancer (1-10). Interferon-alpha (IFNOI) has modest activity against renal cell 
cancer with a response rate of approximately 15 % (11-13). In preclinical 
experiments a synergistic antitumor effect of IL2 and IFNOI has been demonstrated 
(14-16). In early clinical studies the combination of IL2 and IFNOI has yielded 
response rates ranging from 22-40% (17-20). 
The experience with multimodality treatment consisting of IL2, IFNOI and LAK 
is limited. Only one study with this combination has recently been published (21). 
Here, we report a phase II study in which we evaluated the toxicity and antitumor 
efficacy of combination immunotherapy consisting of high-dose IL2 and IFNOI with 
LAK in patients with metastatic renal cell cancer. 
Patients and methods 
Patient population 
Seventy-two patients with progressive metastatic renal cell cancer were studied. 
Their primary tumor was removed by nephrectomy. Eligibility criteria included 
bidimensionally measurable disease, age ,,; 70 years, performance status Kal'llofsky 
index :c: 80 (WHO 0-1), normal organ functions of heart, lung, kidney, bone 
marrow and normal serum bilirubin and coagulation tests. Prior immunotherapy or 
chemotherapy was not allowed. Patients with uncontrolled hypertension, a history 
of myocardial infarction or arrhythmias, central nervous system metastases, 
infections and use of steroid medication were excluded. To exclude significant 
cardiac dysfunction, every patient had to have normal ECG in rest and during 
exercise, cardiac multiple uptake gated acquisition (MUGA) scan and echocardio-
graphy. 
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Treatment 
The treatment schedule is displayed in Figure 1. Seventeen patients were 
entered into a feasibility part of the study (protocol I), using Proleukin IL2 
(Eurocetus, Amsterdam, The Netherlands). Subsequently, aller the treatment 
scheme proved to be safe, an emcacy study (protocol 2) was carried out, using 
Teceleukin IL2 (Hoffmann-LaRoche, Basle, Switzerland). In protocol two 55 
patients were included. Protocol 2 differed from protocol 1 by the addition of IFN", 
(RoferOll, Hoffmann-LaRoche, Basle, Switzerland) to the first 5 days of IL2 
infusion in the 2 induction cycles. In both protocols two cycles of adoptive cellular 
therapy with IL2 and IFN", and LAK were given. Each cycle started with a 120 
hour priming phase of IL2 18 MIU/m'/day administered as a continuous intusion 
(civ) and IFN", 5 MIU/m'/day on days 1-5 (protocol 2) as intramuscular (im) 
injections. Aller a rest period of 24 hours 3 daily runs of Iymphapheresis were 
performed (days 7-9). The autologous lymphocytes obtained were incubated with 
IL2 for 5 days and reinfused on days 12-14. Infusion of IL2 civ (108 h) at the 
same doses as above was resumed at the start of LAK administration, together with 
daily im injections of IFN", 5 MIU/m'/day (days 12-15). IFN", was administered 3 
hours before infusion of LAK. IL2 was reconstituted without carrier protein in 
protocol 1 and with 0.5-0.7% human serum albumin which was a constituent of the 
Teceleukin vials in protocol 2 (22). 
Aller a rest period of 3 weeks this cycle was repeated on day 36. After two 
induction cycles each patient was evaluated for response. Patients with stable 
disease or response were scheduled for maintenance treatment with 4 monthly 
cycles of IL2 18 MIU/m'/day and IFN", 5 MIU/m'/day on days 1-4. 
Paticnts were treated and monitored on the clinical research unit during IL2 
infusions. Vital signs, daily weights and urine volumes were obtained. Fluid 
balance was carefully monitored. Acetaminophen (Paracetamol), 500 mg every 4-6 
hours, was used to control fever. Alizapride (LiticanR), loperamide (ImodiumR), 
and codeine were routinely given to suppress nausea, vomiting, and diarrhea. 
Prophylactic antibiotics were not used routinely. Because of possible 
nephrotoxicity, non-steroid anti-inflammatory drugs (NSAID's) such as indome-
thacine were avoided. Steroids were prohibited. Lymphaphereses and the 
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adnlinistrationoflymphokinesand ... Li\K.\vere .... performed via tunneled central 
venous catheters. Intravenous heparine 15,000 U/day was given during IL2 
treatment episodes to reduce the risk of thrombo-embolic complications. 
Toxicity was graded according to the World Health Organization (WHO) 
criteria (23). For toxicities not included in the WHO guidelines a grading system 
was used ranging from mild (grade 1) to life-threatening (grade 4). Initial treatment 
of hypotension and oliguria consisted of i.v. volume replacement. If volume 
expansion gave no improvement dopamine was added up to doses of 5 "g/kg/min 
to improve renal perfusion. 
days 1 - 5 
t t t t t 
IL2 
t t t t t 
IFNa* 
Days 1-4 
t tt t 
IL2 
t t t t 
IFNa 
Two induction cycles of 35 days 
7 - 9 
~ ~ ~ 
LY-PH 
Four maintenance cycles of 28 days 
IL2: 18 MIU/m2/day CTV. 
LY-PH: Iymphaphercsis. 
JFNa: 5 MlU/m1lday 1M. 
'" not administered in protocol I. 
12 - 16 
t t t t 
IL2 
t t t 
LAK 
t t t t 
IFNa 
Figure 1. Induction and maintenance treatment scheme or IL2 with LAK and IFNa 
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The administration of cytokines. was interrupted if hypotension .WHOgrade 
3/4, not responding to intravenous fluids or dopamine occurred, if oliguria (urine 
production < 15 mllhour) developed or if the creatinine level rose above 400 
pmolli. Other reasons for interruption were metabolic acidosis, severe arrhythmia 
or myocardial ischemia, signs or symptoms of lung edema, agitation or persistent 
confusion not responding to piperidone and elevation of serum bilirubin > 85 
"molli. 
Treatment was discontinued until the side effects improved to grade I toxicity 
or resolved. Reductions in the dose of IL2 and IFN", by 50% were made in the 
subsequent cycles if the patient had experienced hypotension not responding to 
therapy within 8 hours, serum bilirubin > 85 pmol/l or creatinine > 525 "molll 
and WHO grade 3 central nervous system toxicity. 
Treatment was permanently discontinued in case of documented myocardial 
ischemia, WHO grade 4 central nervous system toxicity, serum bilirubin or 
creatinine levels that failed to return to grade I toxicity levels or better. 
Response asseSSlllent 
Before the start of treatment all tumor lesions were assessed by routine CT 
scans of chest, abdomen and brain. The 2 largest perpendicular diameters of each 
indicator lesion were measured and multiplied. The sum of the products of these 
diameters was calculated. This procedure was repeated after 8 weeks and every 2 
months thereafter. Response criteria were used according to the instructions of the 
WHO handbook (23). A complete response (CR) was denned as the disappearance 
of all known disease for at least 4 weeks, a partial response (PR) as a reduction in 
the sum of the products of the 2 largest perpendicular diameters of all lesions by at 
least 50% for more than 4 weeks, without the appearance of any new lesion. Stable 
disease (SD) denoted less than 50% tumor reduction and less than 25% tumor 
progression. Progressive disease (PD) was denned as the appearance of a new 
lesion or an increase in size of more than 25% in any indicator lesion. 
The best response observed in a given patient was noted as the overall 
response. Response duration was calculated from the start of treatment, as were 
time to progression and survival, using the Kaplan-Meier method. 
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Ac!ivationof Iynlphocytes. with IL2 iI/vitro 
Buffy coats harvested by Iymphapheresis (Fenwall CS-3000) were placed into 
culture using a semi-closed bag system: Travenol-Fenwall PL 732 bags, containing 
1500 ml activation medium with 3 x 10' cells/6000 IU IL2/m!. Bags were loaded 
with cells and medium using a Travenol-Fenwall model SA V EX 2 Fluid 
FiIIlWeight Unit. The activation medium consisted of 78 % RPMI-1640, 20% 
AIM-V and 2% autologous human plasma. 2 mM L-glutamine, 50 I'g/ml 
streptomycin, and 40 I'g/ml gentamycin were added to the medium. 
Bags were incubated flat at 3TC, 5% CO" 95% humidity for 120 hours (5 
days). Cells were harvested from the bags with a Fenwall Cell Harvester, washed 
using saline and resuspended in 5 % human serum albumin supplemented with 6000 
IU IL2/ml to a volume of approximately 500 m!. 
Cultures for aerobic an anaerobic micro-organisms were obtained immediately 
after Iymphapheresis, 24 hours prior to cell harvest and 1 hour before reinfusion of 
LAK cells into the patient. Samples of LAK were tested for viability and 
cytotoxicity. 
Immunological studies 
In vitro IL2 activated lymphocytes (LAK) were tested for lysis of K562 and 
Daudi target cells in a 4-hour standard 51Cr release assay. Mononuclear cells 
isolated from patients on treatment were assayed for: a) cell surface markers 
detected by monoclonal antibodies in fluorescence assays and b) cytolysis against 
NK-sensitive (K562) and NK-resistant (Daudi) target cells. The sera from patients 
were collected at predetermined timepoints before and during treatment for the 
assay of IFN/" TNF, IL2, soluble IL2 receptor, IL6, IL8 and CRP. We have 
reported a detailed description of these immunological analyses elsewhere (24). 
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............................. Results 
Patient characteristics 
In total seventy-two patients were entered in both parts of the study; 17 in 
protocol I and 55 in protocol 2. Their median age was 54 years (range 30-69); 47 
(65%) were male and 25 (35%) female. Patient characteristics per protocol are 
summarized in Table I. Ten patients (14 %) received palliative radiotherapy before 
study entry. The median time from initial diagnosis to start of treatment was 6 
months. In 25% of the patients (18/72) the time that elapsed between the primary 
diagnosis of renal carcinoma and the development of metastases was more than 24 
months. 
TABLE 1 PATIENT CHARACTERISTICS 
Age, median (range) 
Male: female 
Karnofsky, median (range) 
Prior radiotherapy 
:2: 2 metastatic organ sites 
Protocol I 
58 (35-68) 
12 : 5 
100 (90-100) 
4 (24%) 
8 (47%) 
Treatment characteristics 
Protocol 2 
54 (30-69) 
35: 20 
100 (80-100) 
6 (11%) 
33 (60%) 
A total of 33 induction cycles were administered to the patients in protocol I. 
One patient developed rapid progressive disease and received only one induction 
cycle. Therapy was continued with maintenance courses in 10 patients, who 
received a number of 37 additional cycles. The actual doses of cytokines 
administered in the 2 induction cycles, expressed as percentage of the planned dose 
were 100% and 94%, respectively. Dose reductions were not necessary. 
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In the ~eGong protocol, 18 patients (33% )received only one . induction cycle: 3 
(5%) died of toxicity, 11 (20%) developed severe adverse events, and 4 patients 
(7%) were taken off study due to rapid progressive disease. Five patients (9%) 
required do~e reductions during the first course because of significant toxicities. Six 
patients (11 %) did not receive any LAK infusions. Of the 37 patients (67%), who 
received a second induction cycle, toxicity necessitated treatment discontinuation in 
4 (7%). Patients received an average of 54% (range 23-100%) and 42% (range 8-
100%) of the planned dose of IL2 and IFN", in the 2 induction courses, 
respectively. An overview of the administered dose levels of cytokines during the 
induction cycles in protocol 2 is presented in Table 2. Twenty-five patients (45%) 
received maintenance therapy for a total of 71 cycles. 
TABLE 2 PERCENTAGE OF PLANNED DOSE OF IL2 AND IFN", ACTU-
ALLY GIVEN DURING INDUCTION TREATMENT IN PROTOCOL 2 
Patients (%) 
Dose Cycle 1 Cycle 2 
> 80% 29 (53%) 8 (15%) 
60-80% 15 (27%) 7 (13%) 
< 60% 11 (20%) 22 (40%) 
0% 18 (33%) 
Treatment results 
Of the 68 evaluable patients in the whole study, 23 responded (response rate 
34%; 95% confidence interval 23-46%). There were 9 complete (CR) and 14 
partial (PR) responses. The treatment results per protocol are listed in Table 3. In 
protocol 1 all 17 patients were evaluable for response and toxicity. The response 
rate was 24% (95% confidence interval 7-50%), with 3 CRs and 1 PRo The median 
duration of response was 18.1 months (range 5.5-56.0+). The median survival was 
13.9 months (range 1.9-56.0+). 
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. In .. protocol 2, fifiy,onepatientswere evaluable for tumor response. Three 
patients died due to toxicity and in the fourth patient post-treatment tumor 
evaluation could not be carried out. These patients were classified as treatment 
failures. Six CRs (12%) and 13 PRs (24%) were achieved for an overall response 
rate of 37% (95% CI 24-52%). The median duration of response was 11.1 months 
(range 2.9-31 + months). The median survival was 16.9 months (range 1.0-48+ 
months). In both protocols the 3-year survival was 35 %. 
TABLE 3 TREATMENT RESULTS 
Protocol 1 Protocol 2 
Evaluable patients 17 51 
Complete response 3 (18%) 6 (12%) 
Partial response (6%) 13 (25%) 
Overall response 4 (24%) 19 (37%) 
Median duration of response 18.1 months 11.1 months 
Median time to progression 6.0 months 5.9 months 
Median survival 13.9 months 16.9 months 
3-Year survival 35% 35% 
Toxicity 
An overview of the most important grade 3/4 toxicities is presented in Table 4. 
Toxicity was predominantly observed during the induction cycles. Frequently 
encountered side effects of any grade were fever, fatigue, malaise, nausea, 
vomiting, diarrhea and skin toxicity. 
There were important differences in the frequency and intensity of observed 
toxicities between the two protocols. Treatment was relatively well tolerated in 
protocol 1 and toxicity did not require dose reductions or permanent treatment 
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dis,ontinuation in any patient, Grade 3/4hypo(ension occurred in9 patients (53%) 
but only necessitated brief interruption of ILl administration, Three patients 
developed supraventricular rhythm disturbances, Only a minority of patients 
experienced relatively mild neurological symptoms, 
In contrast, toxicity was considerable in protocol 2. There were 3 treatment-
related deaths, One patient, a 56-year old male, died of massive pulmonary 
embolism during the convalescence period 3 weeks after the first induction cycle 
was completed, A second patient, a woman of 68-years old, developed intractable 
hypotension and anuria with severe metabolic acidosis on day 4 of the first episode 
with IL2 and IFNa, 
Despite cessation of immunotherapy and termination of its effects by Lv, 
corticosteroids and maximum efforts at the intensive care unit, she died of multiple 
organ failure, Blood, urine and stool microbial cultures were negative, In the third 
patient, a 61-year old woman, hypotension and oliguria occurred on day 2 of the 
second induction cycle, followed by signs of cardiac failure, Echocardiography 
showed hypokinesis of the left ventricle and low ejection fraction, indicating 
cardiomyopathy, Despite the infusion of vasopressors and artificial ventilation, a 
complete atrioventricular block developed, immediately followed by a dying heart 
rhythm, 
Hypotension grade 3/4 was the most common dose-limiting adverse effect 
occurring in 42 patients (76%), In 11 patients (20%) treatment was discontinued 
because of cardiovascular and pulmonary complications: hypotension in 4, 
reversible cardiomyopathy in 3, rhythm disturbances in 2 and lung edema with 
respiratory insufficiency in another 2 patients, Transient renal failure grade 3 
necessitated dose reductions in 12 patients (22%), Six patients (11 %) required dose 
reduction because of grade 3 neurotoxicity, Sixteen patients (29 %) developed 
infections, mostly catheter related, 
Maintenance therapy was given without serious problems in the first protocoL 
In protocol 2 the toxicity was cumulative with regard to fatigue and renal function 
disturbances, leading to premature cessation of treatment in 9 of 25 patients, 
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TABLE 4 GRADE 3 AND 4 TOXICITY 
prot. 1 prot. 2 prot. 1 prot. 2 
Adverse event Grade 3 Grade 4 
Number of patients (%) 
Fever 11 (65) 49 (89) 0 0 
Fatigue 11 (65) 43 (78) 2 (12) 8 (15) 
Anorexia 2 (12) 17 (31) 0 1 (2) 
Skin 1 (6) 10 (18) 0 0 
Gastro intestinal 
Nausea/vomiting 8 (47) 19 (35) 0 (2) 
Diarrhea 3 (18) 12 (22) 0 3 (5) 
Hepatic 
Bilirubine 0 0 0 0 
Alk. phosphatase 2 (12) 8 (15) 0 3 (5) 
Transaminases (6) 12 (22) 0 4 (7) 
Weight gain 0 6 (11) 0 1 (2) 
Hypotension 8 (47) 33 (60) 1 (6) 9 (16) 
Cardiac 
Cardiomyopathy 0 3 (5) 0 2 (4) 
Arrhythmia 3 ( 18) 10 (18) 0 2 (4) 
Pulmonary 3 (18) 13 (24) 0 2 (4) 
Renal failure 0 12 (22) 0 0 
Neurologic 0 13 (24) 0 0 
Hematologic 
Anemia 0 5 (9) 0 0 
Thrombocytopenia 1 (6) 8 (15) 0 2 (4) 
Infection 2 (12) 10 (18) 0 2 (4) 
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Imlnunologicparameters 
We have recently published the results of the immunological monitoring of the 
patients in this study (24). In short, the most important findings were as follows. 
During IL2 infusion peripheral lymphopenia developed, followed by rebound 
lymphocytosis within 2 days after cessation of treatment and a return to normal 
during the subsequent 2 to 3 weeks. The eosinophil counts increased to 
supranormal levels and eosinophilia persisted during the entire treatment period. 
Serum concentrations of the secondary cytokines IFNI' and TNFO' were increased. 
The peak levels of serum IL2, IFNI' and TNFa during IL2 infusion were 2-3 times 
higher in protocol 2 than in protocol I, which was explained by the better 
bioavailibility of IL2 after reconstitution with carrier protein in protocol 2 (22). 
The cell phenotypes of the apheresis products were not significantly different 
between protocols I and 2. Differences between responders and non-responders 
treated according to the two protocols were not signiticant, except for the total 
number of lymphocytes obtained by apheresis, which was higher in responders than 
in non-responders, reaching statistical significance in multivariate analyses (p = 
0.02). 
Clinical prognostic factors 
The effect of the following baseline clinical parameters on antitumor response 
and survival was investigated by multivariate analysis: (i) treatment protocol (1 vs 
2): (ii) performance status (Karnofsky index 80-90 vs 100); (iii) time interval 
between diagnosis of the primary and start of treatment for metastasis (:0; 24 vs > 
24 months); (iv) number of metastatic sites (1 vs ;>: 2); (v) absence vs presence of 
metastases in lymph nodes, lung, liver, bone, abdomen or soft tissues; (vi) weight 
loss. The only parameter of borderline statistical significance was lymphnode 
metastasis: 15 of 33 patients (45%) with predominant lymphnode metastases 
responded versus 8 of 35 patients (23 %) with predominant visceral metastases 
without lymphnodes (p = 0.049). None of the above mentioned parameters had a 
significant effect on survival. 
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Di~cussion 
This triple regimen of high-dose IL2 and LAK in combination with IFNa was 
developed in our institution in 1988. At that time treatment with IL2 combined with 
LAK drew considerable attention. Preclinical animal studies suggested that the 
addition of LAK cells to IL2 could markedly improve antitumor activity. Several 
clinical trials, using high-dose IL2 and LAK reported relatively high response rates 
of 30-35 % in patients with metastatic renal cell cancer (2,25). A European 
multicenter study, in which we participated, yielded a response rate of 27% (3). 
Moreover, animal studies and early clinical studies of the combination of IL2 and 
IFNa appeared very promising with response rates of up to 40% (14-20). 
Consequently, we wanted to investigate whether a triple combination of high-
dose IL2 and LAK with IFNa could yield a high rate of responses of long duration 
in patients with metastatic renal cell cancer. To be able to confirm a predetermined 
response rate of approximately 40 % we planned to perform an extended phase II 
study, comprising ;" 40 patients. We had the intention to use the eventual good 
results of this phase II study as a basis for a subsequent phase III study, to examine 
the relative contribution of LAK. Initially, we were concerned about the use of 
IFNa in the "priming" phase (day 1-5), because IFNa can cause lymphopenia, 
which would jeopardize the lymphocyte harvest during Iymphaphereses. Secondly, 
the addition of IFNa might aggravate IL2 related toxicities, particularly 
hypotension, which would also complicate the Iymphapheresis procedure. 
However, the adverse effects observed in the feasibility part of the study proved to 
be manageable, whereas the treatment results with a response rate of 24 % and a 
median survival of 18 months were reasonable. 
Therefore, we felt encouraged to continue with an efficacy study. After having 
entered 41 evaluable patients, a preliminary analysis demonstrated a response rate 
of 39%, a median duration of response of 14 months, and notably a median 
survival of 28 months (26). Thus, protocol 2 appeared to be highly effective, 
although the adverse effects were much more outspoken than in protocol 1. We 
ascribe this increase in side effects not only to the addition of IFNa into the 
"priming" days 1-5, but particularly to the observed higher serum levels of IL2, 
TNFa, and IFNI' after the change from Proleukin to Teceleukin, which can be 
72 
Chapter V 
explained bythebetter bioavailability of TeceleukiIl (24,27,29). At the (ime of the 
preliminary analysis, we concluded that this combination regimen was the best 
available therapy for metastatic renal cell cancer. Consequently, the protocol was 
kept open for the period of time which was needed for the design and the 
organization of a phase III comparative study of IL2 and IFNa with or without 
LAK. The phase II study, protocol 2 here reported, was closed after 55 patients 
were recruited. The final analysis showed an identical response rate of 37 %, but a 
decrease in the duration of response from 14 to 11 months, and more importantly a 
decrease in the median survival time from 28 to 17 months. Attempts to find 
explanations for this unfavourable development of the treatment results suggested 
that the last 14 patients in the study have a less good performance status and more 
extensive disease. 
The past few years have witnessed a flood of reports on immunotherapy studies 
in renal cell cancer. Trials of IL2 monotherapy in intermediate to high-dose yielded 
response rates from 13-20% (5,30-35). More recent studies of IL2 and LAK 
yielded response rates of 9-20% and could not confirm the earlier reported better 
treatment results compared with IL2 alone (7,25,36,37). In a recent randomized 
trial, combination therapy of IL2 and LAK was not superior to mono therapy with 
IL2 (38). More mature data on the efficacy of the combination of IL2 and IFNa 
also showed lower response rates of 8-12% (37,39,40). In a randomized study the 
efficacy of IFNa and high-dose IL2 versus IL2 alone was compared. The study 
was prematurely closed because the combination was ineffective (10). In a recent 
tinal report of the NCI Surgery Branch dose-escalating study the overall response 
rate of IL2 and IFNa decreased from 38% to 28% (17,41). 
The only other report on a study of IL2, IFNa and LAK with similar dose-
intensity, albeit a different schedule, has yielded a response rate of 24 % and a 
median survival of 8 months (21). The investigators observed a toxicity profile of 
the same nature and severity as we did. Of note, we and others who studied 
intensive regimens of IL2 and IFNa could not administer more than 40-60% of 
these cytokines due to the severity of side-effects (10,21,41,42). 
On the basis of our study and in view of other study data we conclude that 
these high-dose regimens of IL2 and IFNa with or without LAK are not warranted, 
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unless we are able to select reliablythe25,35%ofpatients_lVho lViIIIla"elong, 
term survival as a result of this treatment. 
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Summary 
Background: In a group of patients with metastatic melanoma treated with 
high dose immunotherapy, there was an unexpectedly high incidence of severe 
cardiac adverse effects. 
Methods: Sixteen patients with metastatic melanoma were treated with high 
dose interleukin-2 (IL2) and interferon-alpha (IFNO'). Each treatment cycle 
consisted of IL2 at a dose of 12 MIU/m' and IFNO' at a dose of 3 MIU/m', given 
as intravenous bolus injections every 8 hours on days 1-5, every 3 weeks for a total 
of 3 cycles. Before treatment, careful cardiologic screening was performed, 
including electrocardiogram (ECG), stress test, cardiac multiple uptake-gated 
acquisition (MUGA) scan and echocardiography. During therapy, patients were 
monitored with daily ECG and creatine phosphokinase (CPK) measurements. Once 
cardiac damage was suspected, IL2 and IFNO' were discontinued and echocardio-
graphy, stress test and MUGA-scan were repeated. If indicated, cardiac catheteriza-
tion with endomyocardial biopsies was performed. 
Results: Despite pretreatment cardiac screening, seven patients (44%) exhibited 
myocardial injury. Acute myocardial infarction occurred in one patient, cardiomyo-
pathy developed in four, asymptomatic ECG changes appeared in one and I patient 
died of aClite cardiac arrest. Echocardiography showed hypokinesis and decreased 
left ventricular ejection fraction. These abnormalities disappeared within 6 months. 
Cardiac catheterization in four affected patients revealed normal coronary arteries, 
but endomyocardial biopsies showed interstitial edema, vacuolation and degenerati-
on of myocytes. Electron-microscopic examination showed fragmentation of 
myofibrils, swelling of mitochondria and loss of mitochondrial cristae. 
Conclusions: This intensive treatment schedule of IL2 and IFNO' is prohibited 
by severe and life-threatening cardiac toxicity. 
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Introduction 
Interleukin-2 (IL2), either alone or in combination with other cytokines or 
activated lymphocytes, has shown antitumor activity against several forms of 
cancer, especially renal cell carcinoma and melanoma (1-5). The side effects ofIL2 
are considerable, including a nu-Iike syndrome with fever, rigors, lethargy, nausea, 
vomiting and diarrhea. In addition, cardiovascular, pulmonary, renal, hepatic and 
hematologic adverse effects have been observed (6,7). Hemodynamic and pulmo-
nary disturbances are caused by a decrease in peripheral vascular resistance and a 
capillary leak syndrome, which can lead to an increased cardiac index, decreased 
left ventricular function, hypotension, oliguria, renal failure, peripheral and lung 
edema (8-11). 
IL2 can also induce atrial and ventricular arrhythmias, angina pectoris and 
acute myocardial infarction (1,8,12-14). Autopsies and endomyocardial biopsies 
have shown myocarditis with myofibre degeneration and foci of myocyte necrosis. 
In most patients with myocarditis variable degrees of lymphocytic or eosinophilic 
infiltrations were demonstrated (15-18). It has been reported that treatment with 
other cytokines such as interferon-alpha (IFNlX) and tumor necrosis factor (TNF) 
can also be associated with similar patterns of myocardial damage (19-23). 
A recent National Cancer Institute Surgery Branch study suggested a steep dose 
response relationship for the combination of IL2 and IFNlX in the treatment of 
metastatic melanoma (3). Consequently, we started a phase 2 study with this high 
dose intravenous bolus regimen of IL2 and IFNlX in an attempt to confirm the high 
response rate of approximately 40%. However, we were confronted with a high 
incidence of severe and life-threatening cardiotoxicity that prohibited additional use 
of this regimen. This article reports the clinical and morphologic lindings. 
Patients and methods 
Thirty patients with metastatic melanoma were required to estimate a response 
rate of 40%. Eligibility criteria included histologic proof of melanoma, bidimensi-
onally measurable metastases, Karnofsky performance status index of 80 or greater, 
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age 18-70 years, a normal computed tomography scan of the brain, normal organ 
functions of heart, lung, kidney, and bone marrow; and normal results of serum 
bilirubin and coagulation tests. 
Initially, cardiologic screening consisted of a 12-lead electrocardiogram (ECG). 
However, two of the first live patients treated in the protocol experienced severe 
cardiotoxicity. We decided, that every new patient had to undergo an extensive 
evaluation of cardiac function, which included a 12-lead ECG, stress test, cardiac 
multiple uptake-gated acquisition (MUGA) scan and echocardiography. Normal 
results of all these tests were required; otherwise, the patient was ineligible. In 
addition, patients with uncontrolled hypertension and a history of myocardial 
infarction or arrhythmias were excluded. Prior immunotherapy was not allowed. 
Prior chemotherapy was permitted. Written informed consent was obtained from 
each patient. 
The treatment plan consisted of three cycles. Each cycle comprised IL2 
(Hoffmann-La Roche Inc. Basle) at a dose of 12 MIU/m' and IFN" (Hoffmann-La 
Roche Inc. Basle) at a dose of 3 MIU/m', each given as an intravenous bolus 
injection every 8 hours on days 1-5, every 3 weeks. 
Patients were treated and monitored on the clinical ward with frequent asses-
sments of vital signs, weight and fluid balance. Hematologic and biochemical blood 
tests, including creatine phosphokinase (CPK) were performed on days 1, 3 and 5 
of each treatment cycle. A l2-lead ECG was obtained daily during therapy. 
Acetaminophen was used to control fever. Vomiting and diarrhea were treated 
symptomatically with alizapride and loperamide. Corticosteroids were not permit-
ted. 
Toxicity was graded according to the World Health Organization (WHO) 
criteria (24). Initial treatment of hypotension and oliguria consisted of Lv. volume 
replacement. If volume expansion gave no improvement, dopamine was added at 
dosages as great as 5 I'g/kglmin to improve renal perfusion. If higher dosages of 
dopamine were required, the patient was transferred to the intensive care unit and 
the administration of IL2 and IFNa was discontinued. Treatment was permanently 
discontinued if grade 3 cardiovascular toxicity or neurotoxicity occurred. In all 
other cases of grade 3 toxicity (except fever, nausea/vomiting, diarrhea) treatment 
was discontinued until the side effects improved to grade I or resolved. Resumpti-
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on of treatment was allowed at 50 % of the doses in the next cycle if grade 3 
toxicity resumed to grade I or less. Patients with ECG changes or precordial pain 
were examined by the cardiologist. A full re-examination was performed, including 
stress test, echocardiography and ejection fraction measurement (MUGA-scan). If 
indicated, cardiac catheterization with endomyocardial biopsy was performed. 
Results 
Sixteen patients, 9 men and 7 women in excellent clinical condition (median 
Karnofsky index, 100), with a median age of 47 years (range, 29-61) were treated. 
Seven (44 %) achieved a response (two complete and five partial). The study was 
closed prematurely becuase of prohibitive cardiac toxicity. 
Severe and life-threatening cardiotoxicity occurred in seven patients, one with 
myocardial infarction, and four with cardiomyopathy; one patient died of cardiac 
arrest, and one had asymptomatic ECG changes. ECG abnormalities occurred 
between day 4 and 64 (mean day 23, median day 5) after the start of treatment. 
The intended treatment also was hampered by other serious adverse effects. 
Toxicities, that led to dose reduction of 50% in subsequent cycles were hypotension 
and anuria in two patients, intractable diarrhea in one and hyperbilirubinemia 
greater than 6,0 mg/dl ( greater than 100 "molll) in one patient. Treatment was 
terminated prematurely in three patients because of neurotoxicity. One of these 
patients also developed a cardiomyopathy. Catheter related sepsis occurred in one 
patient, necessitating brief interruption of treatment. 
Patients with cardiotoxicity received 82 %, 54 % and 53 % of the planned total 
dose of IL2 and IFNa in the three respective treatment cycles. The entire patient 
group received 88%, 65% and 51 % of the planned dose, respectively. 
The details about patient characteristics, onset and type of cardiotoxicity, the 
results of cardiologic examinations and the final cardiac function status are reported 
here and summarized in Table I. 
83 
Chapter VI 
TABLE 1 IL2 AND IFN", ASSOCIATED CARDIAC DYSFUNCTION 
PI. 
2 
3 
4 
5 
6 
7 
AgelSex Interval Ischemia' Hypo-
start kinesia 
treatment RV/LV # 
to ECG 
changes 
(days) 
45/m 5 3 +1+ 
32/f 4 3 +1+ 
291m 56 NE 
50/f 21 2 +1+ 
40/m 5 +1-
43/f 5 2 -1+ 
43/m 64 acute NE 
cardiac 
arrest 
hchemia: I = negative T-waves without ~ympt(lmes 
2 = nngina, ischemic changes on EeG 
3 = acute myocanlial infarction 
Myocard~ Improvement 
itis@ cardiac function 
NE + 
+ + 
NE NE 
+ + 
+ + 
+ + 
NE NE 
@ Microscopic examination of endomyocanJiaJ biopsies showing degenerative changes of the myofibrils and/or cellular 
infiltration 
1/ Echocardiographic antl/o[ cardiac calherizalion finding~ 
NE: Not Evaluated 
RV: Right Venlricle 
LV: Left Ventricle 
Patient 1 had signs of an acute myocardial infarction at day 5 of the first 
course. At that moment, treatment related toxicity consisted of fever, nausea, 
diarrhea and hypotension grade 2. The clinical picture started with chest pain, 
characteristic ECG changes consisting of ST -elevations in leads II and III and 
elevation of CPK-MB. One day later, he experienced severe pulmonary edema, 
hypotension and hypoxemia. He was transferred to the intensive care unit and 
treated with diuretics and vasopressors for a period of 4 days. Echocardiography 
demonstrated hypokinesia of the ventricular septum, the anterior wall and the apex 
of the left ventricle. He recovered uneventfully and was discharged 2 weeks later in 
good clinical condition without any physical restriction. Treatment with IL2 and 
IFNa was discontinued permanently. No cardiac catheterization was performed. 
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Subsequent ECG showed a negative T-wave in lead III and a small q-wave in lead 
aVF. 
Patient 2 experienced chest pain and hypotension on day 4 of the first cycle. 
During the first 3 days only minor toxicities such as fever, chills, nausea and 
vomiting were observed. Typical ECG changes and elevation of CPK-MB sugge-
sted myocardial infarction. Echocardiographic examination on day 5 revealed 
hypokinesia of the ventricles. The left ventricle ejection fraction (LVEF) decreased 
from a pretreatment value of 67% to 23% (normal value c: 50%). Cardiac 
catheterization was performed on day 11. Normal curonary arteries were found. 
Endomyocardial biopsies showed degeneration of the myofibrils with interstitial 
edema and lymphocytic cell infiltration compatible with myocarditis. The biopsy 
procedure was complicated by cardiac perforation with symptoms of cardiac 
tamponade. Successful pericardiocentesis was performed and the patient recovered 
uneventfully. Immunotherapy was discontinued permanently. An echocardiogram 2 
months later revealed normal cardiac dimensions with an ejection fraction of 55 %. 
ECG was normalized at that time. 
Patient 3 received three full cycles of therapy without any severe or Iife-
threatening toxicity and without cardiac symptoms or complaints. The most 
important adverse effcct present during immunotherapy was hyperbilirubinemia 
(102 /lmolll). However, on day 56 after the start of treatment, 8 days after the 
completion of IL2 and IFN", administration, negative T -waves were observed in the 
precordial leads of a routine ECG. His malignant disease was progressive at that 
time and the patient returned abroad without additional cardiologic evaluation. 
Patient 4 underwent the first cycle uneventfully. The main adverse effects were 
fever, fatigue, nausea and vomiting. At the start of the second cycle she complai-
ned about chest pain during rest and dyspnea during exercise. Her ECG revealed 
negative T-waves in standard leads I, II, III, aVL, aVF and in the precordial leads 
V3-V6 (Figure 1, top). CPK-MB was not elevated. Echocardiographic examination 
revealed hypokinesia of the ventricles. The ejection fraction decreased from 60% to 
45%. 
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Figure 1 Electrocardiogram of patient 4 (Top), Negative T-waves in the standard and precordial leads 
(I, II, III, aVL, aVF, V2-V6), as detected 3 weeks after therapy was started (Bottom). A normalization 
of the EeG 4 months latcr. 
The second cycle was withheld and cardiac catheterization was performed on 
day 28. Normal coronary arteries were found. Endomyocardial biopsy was taken 
from the left ventricle and histologic examination revealed interstitial edema, 
vacuolation of the myocytes and myofibrillar loss. No lymphocytic or eosinophilic 
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infiltrates were seen (Figure 2). Electron microscopic examination of these speci-
mens, as shown in Figure 3, revealed degenerative changes of the myofibrils with 
myotibrillar loss, mitochondrial changes consisting of abnormal shape and size and 
loss of cristae. The symptoms disappeared during the course of several weeks. 
Figure 2 Endomyocardial biopsy from patient 4 obtained 4 weeks after therapy was started. Myofi-
brillar loss, focal vacuolation of the myocytes, and disruption of the normal architecture willI interstitial 
edema. No lymphocytic or eosinophilic infiltration (hematoxylin and eosin; magnification x 400). 
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Echocardiographic hypokinesia improved gradually during a period of 2 months 
with normalization of the left and right ventricular dimensions and wall move-
ments. ECG normalized after 4 months (Figure 1, bottom). IL2 and IFN", were not 
restarted. 
Figure 3 Eleclronmicroscopic picture of the same specimen as shown in Figure 2 showing degenerative 
changes with myofihrillar loss, abnormal shapes and sizes of Ihe mitochondria (arrow) with loss of 
cristae (magnification x 7000). 
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Patielll 5 had asymptomatic ECG changes detected at day 5 of the first course 
with negative T-waves in standard leads III and aVF. An additional significant side 
effect was confusion. Echocardiographic examination revealed focal akinesia at the 
inferior region of the heart. The LVEF decreased from 75 % to 42 %. Cardiac 
catheterization, performed at day 21, showed normal coronary arteries. Endomyo-
cardial biopsies taken from the left and right ventricle demonstrated the same light 
and electron microscopic findings as in patient 4. Because of the focal localization 
of the myocardial abnormalities and the recovery of the L VEF we deemed it 
acceptable to re-treat the patient with IL2 and IFN", in reduced doses. However, on 
day 4 of the second cycle, there was worsening of the ECG changes with negative 
T-waves occurring in leads V3-V5 and aggravation of the preexisting changes in 
leads III and aVF. Treatment was stopped permanently. 
Patient 6 received the first cycle with the usual adverse effects caused by IL2 
but without severe hypotension. On day 5 she reported an oppressive sensation on 
the chest, accompanied with negative T-waves and ST-elevations in leads III, aVF, 
V3-V6. Echocardiographic examination revealed hypokinesia in the anterolateral 
and posterobasal region. CPK-MB was slightly elevated, indicating myocardial 
damage. The LVEF decreased from 78% to 44%. Cardiac catheterization on day 8 
showed normal coronary arteries. Endomyocardial biopsies taken from the left and 
right ventricle revealed only interstitial edema. There was a normal architecture of 
the myofibrils. No lymphocytic or eosinophilic cell infiltrates were seen. Because 
of the absence of damage in the myofibrils, therapy with cytokines was resumed, 
despite the persistance of negative T-waves in III and aVF. The doses were 
reduced with 50%. The patient received the second and third cycle without 
worsening of her ECG. Two months after completion of therapy, there was 
normalization of the ECG and echocardiogram. 
Patient 7 died at home 5 weeks after the completion of three cycles of IL2 and 
IFN",. Ten years earlier he was examined by a cardiologist because of palpitations. 
Cardiologic examination at that time revealed a supraventricular tachycardia and a 
prolapse of the mitral valve. A diagnosis of viral myocarditis was suggested, but 
not proven. He was treated with a (3-blocking agent (atenolol) until the start of 
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immunotherapy. His pretreatment cardiologic screening was normal. Because. of the 
absence of cardiac signs and symptoms, the patient was accepted for the protocol. 
During the course of the study there were no ECG abnormalities. Treatment was 
complicated by the occurrence of hypotension grade 3 and neurotoxicity grade 3 in 
the third cycle. The patient made a complete recovery. One month after the 
completion of the third cycle of therapy, he was seen by the cardiologist because of 
palpitations. A supraventricular tachycardia was demonstrated, but echocardiograp-
hy and results of a stress test were normal. He was treated with digoxin and 
flecainide. One week later, he was found dead at home. No autopsy was perfor-
med. 
Discussion 
A wide variety of cardiac toxicities have been attributed to IL2 therapy, 
including arrhythmias, ischemia, myocarditis, and hypocontractility. Arrhythmias, 
mostly supraventricular, occur in as many as 10% of patients (1,4,7,9). In large 
series, ischemia was reported in 3-10% of patients and myocardial infarction in 1-
4% (1,7,9). In addition, several incidental cases of myocardial infarction and 
cardiomyopathy have been described (8,13,15-18,25). Strikingly, in most of these 
patients there was no evidence of coronary artery disease at coronary angiography 
or autopsy (8,9,13). Cardiomyopathy related decrements in left ventricular ejection 
fraction and echocardiographic abnormalities appear to be reversible and disappear 
during the course of several months (9,10,25). 
Histologic examinations of cardiac biopsies have basically shown the picture of 
degenerative changes and necrosis of myocytes, with or without eosinophilic or 
lymphocytic infiltration. The suggested mechanisms underlying these abnormalities 
include toxic and allergic reactions (15-18,20,22). 
Interferons also havc been reported to be a potential cause of cardiotoxicity 
with features similar to that associated with IL2 administration. The frequency of 
severe signs and symptoms is reported to be 1-3% (19-22). 
We report an unexpectedly high incidence of severe and life-threatening 
cardiotoxicity in a patient group treated with high doses of Lv. bolus IL2 and 
IFNa. One patient experienced an acute myocardial infarction and four patients 
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experienced cardiomyopathy. Onepatientdied of an acuteeardiac arrest-His death 
may have been caused by IL2 and IFNc< therapy, but a relation with flecainide 
cannot be excluded, because this drug can induce re-entrance arrhythmias and 
cardiac arrest (26,27). The occurrence of cardiac problems appeared unpredictable 
on the basis of age, performance status and cardiovascular functional status at the 
start of treatment. Ischemic heart disease before immunotherapy in our series was 
ruled out by extensive cardiologic examinations. 
Most studies of the combination of IL2 and IFNc< have not shown an increased 
frequency and severity of cardiac adverse events, compared with what would be 
expected of IL2 administration alone (28-36). In reports, describing the use of low-
dose intravenous or subcutaneous IL2 and IFNc<, cases of severe cardiotoxicity are 
rare (28,32,36). Most IL2 trials used continuous infusion in doses not exceeding 18 
MIU/m'/day, and patients with cardiotoxicity were only incidentally encountered 
(29-31,33-35). In one such a study using IL2 (7,5-15 MIU//m'/day, continuous 
Lv.), IFNc<, LAK and immunomodulatory doses of chemotherapy, 10% of patients 
experienced myocardial infarction or cardiomyopathy (37). In trials, using high 
doses of Lv. bolus IL2 (18-24 MIU/m'/day) alone 01' in combination with IFNc< 
Lv. a 9-14 % incidence of myocardial infarction and myocarditis has been observed 
(38,39). In the National Cancer Institute Surgery Branch study with high-dose IL2 
and IFNc< in a similar schedule as ours, 25% of treatment courses were associated 
with an increase in creatine phosphokinase MB, indicating myocyte damage (3). 
Thus, severe cardiac toxicity seems to be related to the use of high-dose IL2, 
whereas synergism between cytokines in causing myocardial damage cannot be 
excluded. The use of Lv. ultra-high bolus administration appears to be an especial-
ly great risk factor. 
The histologic changes that we observed were primarily degenerative. Of the 
four patients who underwent biopsies, only one had an infiltrate of lymphocytes. 
Other findings were interstitial edema, vacuolation and necrosis of myocytes and 
myofibrillar loss. Electronmicroscopic examination of the biopsies of one patient 
revealed degenerative changes of the myofibrils, mitochondrial changes and loss of 
mitochondrial cristae. These morphologic changes are similar to the type of 
cardiotoxicity that has been reported for anthracyclines (40,41). 
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Weconclu<ie that this intensive s,heduleafLv. bolus IL236 MIU/m'/day and 
IFNO! 9 MIU/m'/day for 5 days is responsible for an unacceptable incidence of 
severe and life-threatening cardiotoxicity. This finding is additional supported by 
our not observing signs or symptoms of ischemia or cardiomyopathy in a consecuti-
ve cohort of 25 identical patients treated with the same daily dosages of IL2 and 
IFNO! for 3 instead of 5 days per cycle (60% of the initial dose-intensity). 
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Summary 
Purpose: To analyse the putative relationship between immunotherapy 
associated dysthyroidism and the probability of a tumor response. 
Patients and methods: A total of 89 consecutive patients with advanced cancer 
were treated with interleukin-2 (IL2)-based immunotherapy in a prospective study. 
Results: Twenty patients developed thyroid dysfunction. Repeatedly positive 
tests for thyroid antibodies developed in 28% of the patients. Twenty-two patients 
achieved a response. There was no relationship between the formation of antibodies 
and the probability of response. There appeared to be a trend towards a 
relationship between thyroid dysfunction and response (p=O.23). A strong 
relationship was found between response on the one hand and cumulative dose of 
IL2 (p=O.Ol) and treatment duration with IL2 (p=O.025) on the other hand. The 
frequency of thyroid dysfunction was also significantly correlated with treatment 
duration (p=O.OOl). After adjustment for cumulative dose of IL2 and treatment 
duration, no relationship between thyroid dysfunction and response remained 
(p=O.99). 
Conclusion: There is no relationship between thyroid dysfunction and the 
probability of tumor response. Thyroid dysfunction is merely a function of 
treatment duration and cumulative dose of IL2. 
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Introduction 
In 1988, Atkins et al reported a high incidence of hypothyroidism in 
interleukin-2 (IL2)-treated patients (1). This phenomenon appeared to be related to 
a higher probability of tumor response. Several other investigations have been 
carried out to examine this potential relationship (2-6). We have performed a 
prospective study in 89 consecutive patients with metastatic solid tumors, who were 
treated with IL2-based immunotherapy. Here we report an analysis of the incidence 
of thyroid dysfunction in relationship to tumor response, the cumulative dose of 
IL2 received, and the duration of IL2 treatment. 
Patients and methods 
Eighty-nine patients with progressive measurable metastatic solid tumors were 
treated with IL2-based immunotherapy. Thirty-two were women, and 57 were men. 
The median age was 51 years, range 22-69. Thirty-eight patients had melanoma, 39 
rellal cell cancer, 8 non-small cell lung cancer, I breast cancer, 1 gastric cancer. 1 
sarcoma, and I had germ cell cancer. Thus, 77 patients (87%) had melanoma or 
renal cell cancer, which are the tumor types most responsive to IL2. Treatment 
regimens comprised high dose IL2 continuous intravenous infusion (c.Lv.), high-
dose IL2 c.L v. with interferon-alpha (IFNa) subcutaneously (s.c.), high-dose IL2 
bolus Lv. with IFNa bolus Lv., low-dose IL2 c.Lv. with IFNa s.c., high-dose IL2 
c.Lv. with ex vivo IL2-activated lymphocytes (LAK), and high-dose IL2 c.Lv. with 
IFNa s.c. and LAK. Table 1 shows the distribution of patients according to tumor 
type and protocol regimens. Three types of IL2 preparations were used with 
different specific activities on a per weight basis. The activaties were converted 
into international units (LU.) for the purpose of this analysis: 
3 million Cetus units = 6.9 million Roche units = 6.9 Olaxo units = 18 million 
international units (MIU). 
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Thyroid studies 
Serial determinations of serum concentrations of thyroxine (T4) and thyroid 
stimulating hormone (TSH) were performed every 4 weeks. In case of abnormal 
thyroid function these tests were performed every week. Serum T4 concentrations 
were measured with a radioimmunoassay (normal value 60-160 mllol/l) and serum 
TSH with a very sensitive immunoradiometric assay (normal value 0.10-4.0 
mIU/I). Thyroid dysfunction was defined as follows: hypothyroidism, T4 < 60 
nmol/l and TSH > 4.0 mIUIl; subclinical hypothyroidism, TSH > 4.0 and T4 60-
160; hyperthyroidism, TSH < 4.0 and T4 > 160. Biphasic thyroid dysfunction 
was defined as hyperthyroidism followed by hypothyroidism. All patients who 
developed decreased T4 levels were treated with levothyroxine substitution therapy. 
Antithyroglobulin and antithyroid microsomal antibodies were determined semi-
quantitatively by an immunofluorescence method. The results were reported as 
positive, weakly positive or negative. This method was developed and performed 
by the Central Laboratory of the Netherlands Red Cross Blood Transfusion 
Service. Two micron frozen sections of thyroid tissue derived from patients 
operated for thyrotoxic goiter were incubated with patients serum (dilution I: 10) 
for 30 minutes. In a second 30 minutes incubation step, fluorescein isothiocyanate-
labeled anti-human sheep immunoglobulin Was added. Hereafter the samples were 
examined by fluorescence microscope. 
Results 
Twenty patients (22 %) developed thyroid dysfunction. Seventeen of them 
(85%) showed an initial rise of T4 > 160 nmolll (peak values 161-320) with a 
concomitant decrease of TSH < 0.10 mIUIl (hyperthYl'Oidism) at 3-12 weeks 
(median, 7 weeks) after the start of IL2. In 9 of them, a hiphasic pattern was seen 
with a subsequent drop of T4 below normal and an increase in TSH with peak 
levels of 12-48 mIU/I (hypothyroidism). In 2 patients, T4 normalized in the 
presence of elevated TSH (subclinical hypothyroidism). Both T4 and TSH 
normalized in 3 patients. The course of thyroid dysfunction could not be followed 
in 3 patients because of early death due to cancer. Hypothyroidism without an 
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initial phase of hyperthyroidism was seen in 3 patients. Hypothyroidism emerged 
between 6-15 weeks (median, 11 weeks) after the start of IL2. Goiter did not 
occur. 
The 12 patients with T4 < 60 nmolll and TSH > 4.0 mIUIi were treated with 
levothyroxine during further immunotherapy. After cessation of IL2, levothyroxine 
was stopped and thyroid function became normal in the 10 patients who could be 
followed. The remaining 2 patients died of progressive cancer. 
Antithyroglobulin and antimicrosomal antibody determinations before and 
during immunotherapy were available in 18 of the 20 patients with thyroid 
dysfunction. Before treatment, 2 patients had a weakly positive antibody test, which 
persisted during IL2 therapy. Of the remaining 18 patients, 6 (33%) developed a 
weakly positive test at only one point in time and 5 (28%) became permanently 
seropositive. The tests became positive simultaneously with the development of 
high T4 values. 
Thyroid antibodies were determined in 62 of the 69 patients who remained 
euthyroid. Before therapy, 2 patients were positive and during treatment antibodies 
became positive in 3 other cases. 
In 4 patients an 1231 thyroid uptake scan was performed in the period of high T4 
values. Thc observed uptake was only 0.5%, 1%,2% and 2%, respectively. 
Abnormal thyroid function was observed in 5 of the 6 treatment regimens. The 
incidence varied from 0-53% (Table 1). There was a highly significant difference 
(p ~0.005) between the short-term and the low-dose IL2 regimens (schedules 3 and 
4) on the one hand and the high-dose prolonged IL2 regimens on the other hand. 
Twenty-two of the 89 patients achieved a response (25%); 9 complete and 13 
partial. Response rates varied greatly between the different regimens, even within 
one and the same tumor type (Table 1). Seven of the 20 patients with thyroid 
dysfunction (35%) achieved a response, as compared to 15 of 69 euthyroid patients 
(22 %). This trend towards a difference does not reach statistical significance 
(p~0.23 chi-square test). Thirty-one percent of the patients with positive 
antibodies, and 25% of the patients with negative antibodies achieved a response. 
This difference is not signiflcant. 
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TABLE 1 RATES OF THYROID DYSFUNCTION AND RESPONSE IN 
DIFFERENT PROTOCOLS 
Regimen Malignancy Pts Thyroid Resp 
Dysfunction 
N (%) N (%) 
1. IL2 c. Lv. (phase I) Miscellaneous 8 3 (38) 2 (25) 
2. IL2 c.Lv. + IFN" s.c. Melanoma 17 9 (53) 2 (12) 
3. IL2 bolus Lv. + IFN" bolus Lv. Melanoma 18 I (6)' 7 (39) 
4. IL2 low dose c.Lv. + IFN" s.c. NSCLC 8 0(0)' o (0) 
5. IL2 c.Lv. + LAK Renal 6 2 (33) I (17) 
6. IL2 c.L v. + IFN" Lm. + LAK Renal 32 5 (16) 10 (31) 
Total 89 20 22 
* p~O.005 
NSCLC: nOll-small cell lung cancer 
Data regarding the influence of the cumulative dose of IL2 on the development 
of thyroid dysfunction and its relationship with tumor response are presented in 
Table 2. After dichotomizing cumulative dose around the mid-range IL2 dose of 
400 MIU/m', there are more cases of thyroid dysfunction in the higher dose group, 
but this difference does not reach significance (p=0.09 chi-square test). However, 
a significantly greater proportion of the responding patients ('1,,=41 %) received a 
cumulative dose > 400 MIU/m') than the non-responding patients ('°167= 15%) 
(p=0.003). 
TABLE 2 INFLUENCE OF CUMULATIVE DOSE OF IL2 (MIU/m') ON 
FREQUENCY OF THYROID DYSFUNCTION AND RESPONSE 
Thyroid Cumulative dose Response Cumulative dose 
function 
,,; 400 > 400 ,,; 400 > 400 
Abnormal 13 7 yes 13 9 
(19%) (36%) (19%) (47%) 
Normal 57 12 no 57 10 
Total 70 19 Total 70 19 
P = 0.09 P = 0.01 
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Table 3 shows the influenceof duration of therapy calculated as total days of 
IL2 administration on the development of thyroid dysfunction and the relationship 
with response. Treatment duration is dichotomized around the mid-range value of 
25 days. A treatment duration of 25 days or more resulted in a higher frequency of 
thyroid dysfunction (45% vs 10%) (p<O.OOI) and is correlated with a higher 
response rate (p=0.025). When treatment duration is calculated as weeks from the 
first until the last IL2 dose, including rest periods, the results are identical at a 
mid-range value of 12 weeks (data not shown). 
TABLE 3 INFLUENCE 011 IL2 TREATMENT DURATION (CALCULATED 
AS TREATMENT DAYS) ON FREQUENCY OF THYROID DYSFUNCTION 
AND RESPONSE 
Thyroid Treatment duration Response Treatment duration 
function 
< 25 ~ 25 < 25 ~ 25 
days days days days 
Abnormal 6 14 Yes 10 12 
(10%) (45%) (17%) (39%) 
Normal 52 17 No 48 19 
Total 58 31 Total 58 31 
P = 0.001 P = 0.025 
Because of the apparent influence of cumulative dose of IL2 and treatment 
duration on the development of thyroid dysfunction, and the fact that responding 
patients received higher cumulative doses of IL2 with longer treatment duration 
(Tables 2 and 3), it is possible that a putative relationship between thyroid 
dysfunction and tumor response is biased by cumulative dose and/or treatment 
duration. Therefore, we analysed the response and thyroid dysfunction relationship 
in the four dose and treatment-duration strata as shown in Table 4. With the use of 
the Mantel-Haenszel approach for combining 2x2 tables (7), it is clear that after 
adjustment for cumulative dose and treatment duration no statistically signitlcant 
relationship can be demonstrated betwcen thyroid dysfunction and response 
(p=0.99). 
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TABLE 4 RELATIONSHIP OF'THYROIDDYSFUNCTION AND TUMOR 
RESPONSE WITHIN 4 TREATMENT STRATA WITH IL2 (F'ORMED BY 
CUMULATIVE DOSE AND TREATMENT DURATION 
Cumulative Treatment Response Thyroid Euthyroidism 
Dose Duration 
(MIU/m') (days) Dysfunction 
0-400 1-24 yes 1 8 
no 4 43 
0-400 25-52 yes 3 1 
no 5 5 
401-800 1-24 yes 0 I 
no 1 0 
401-800 25-52 yes 3 5 
no 3 6 
P = 0.99 
DisclIssion 
We report on a prospective study of thyroid function in 89 consecutive patients 
treated with IL2-based immunotherapy. The observed frequency of thyroid 
dysfunction in this series is 22 %. Originally, hypothyroidism was the only 
recognized form of IL2-induced thyroid dysfunction (I), but later reports have 
shown that hyperthyroidism preceeds hypothyroidism in the majority of cases (2-
6,8). We have seen this biphasic pattern in 65% of the patients who developed 
thyroid dysfunction. This phenomenon can also be produced by interferons (9-11). 
It has been suggested that IL2 can induce autoimmune thyroiditis (2,5). Our 
findings of biphasic dysfunction, the development of thyroid antibodies and the 
absence of 1231 uptake are consistent with that concept. In a recent report, Jacobs et 
al (8) draw attention to the possibility of a non-autoimmune toxic side effect of 
IL2-based immunotherapy as a second mechanism. One argument to support that 
hypothesis was the fact that thyroid function rapidly normalized in 75% of their 
affected patients after cessation of immunotherapy. To date, our findings are 
identical with a 100% recovery in the patients followed. 
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A total of 61 % of our patients with thyroid dysfunction developed thyroid 
antibodies, demonstrated by a semi-quantitative immunofluorescence method, which 
is high in comparison with other reports (1-6,8). However, if we exclude the 
patients who were weakly seropositive at only one point in time, the incidence of 
antibody formation is 28 %, which is in agreement with the findings in the 
literature. 
The reported frequency of thyroid dysfunction in the literature varies from IS-
91 % (1-6,8). These differences may be the reflection of additional treatment 
components such as IFN" and LAK, but may also be a function of treatment 
duration and cumulative doses of drugs. 
The main purpose of this study was to determine a possible relationship 
between thyroid dysfunction associated with immunotherapy and the probability of 
response, as well as to elucidate the eventual influence of cumulative dose of IL2 
and treatment duration. Since our analysis comprises 6 treatment schedules, we 
chose to calculate treatment duration as the total number of days that a patient had 
actually received IL2, as well as the period from the start to the finish of IL2 
therapy. A trend towards a higher response rate was observed in patients who 
developed thyroid dysfunction (3S vs 22%). Table 2 shows that 7 (36%) of 19 
patients who received more than a cumulative dose of 400 MIU/m' of IL2 
developed thyroid dysfunction and that 9 (47%) of these patients obtained a 
response. Similarly, Table 3 shows that 14 (45%) of 31 patients with a treatment 
duration of 25 days or more developed thyroid dysfunction and that 12 (39%) of 
these patients achieved a response. The relationship between thyroid dysfunction 
and cumulative dose of IL2 is of borderline significance (p=O.09). The relationship 
between thyroid dysfunction and treatment duration is highly significant (p=O.OOI). 
In addition, the probability of response is significantly correlated with cumulative 
dose of IL2 (p=O.OI) and treatment duration (p=O.02S). 
When we finally analyzed the relationship between thyroid dysfunction and 
response to treatment after adjustment for cumulative dose and treatment duration, 
no prognostic influence of thyroid dysfunction on the probability of response 
remained (Table 4, p=O.99). Consequently, we conclude that there is no 
correlation between thyroid dysfunction and tumor response. Thyroid dysfunction is 
merely a function of treatment duration and cumulative dose of interleukin-2. 
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Chapter VIII 
Intl'oduction 
Immunotherapy, unlike chemotherapy and endocrine therapy, which are now 
established treatment methods in cancer, is still in the developmental stage, 
although it has a long history. At the beginning of this century Paul Ehrlich was 
the first, who proposed that the cellular immune system has a role in the recogniti-
on and destmction of malignant cells (1). However, in the past, efforts to use 
immunotherapy as a strategy against cancer were by and large unsuccessful due to 
the inability to evoke an immune response against tumor-associated antigens and 
the lack of immunocompetence of the host immune system. 
Thanks to recent biotechnological advances interest in this treatment mOdality 
has been renewed. The antitumor activity of biological response modifiers such as 
interieukins and interferons in vitro and in vivo was impressive enough to expect 
them to exhibit significant anti-cancer activity in men. Dramatic responses and 
rejection phenomena in animal models led to high hopes tllat cytokines might be a 
panacea for the treatment of cancer. The cloning of cytokine genes enabled the 
production of large amounts of these substances by recombinant technology and the 
beginning of clinical trials. In humans, only renal cell carcinoma and melanoma 
have some immunogenic properties and investigators have concentrated their 
treatment efforts on these tumor types. The most significant results are obtained 
with interleukin-2 (ILl) and interferon-alpha (IFNa). For this reason we will focus 
in this review on the use of these two cytokines in renal cell cancer and melanoma. 
Rationale fol' the use of immunotherapy in cancel' 
Studies already published in the 1960s provided the first evidence that human 
cancers can evoke both humoral and cell mediated immune responses (2-5). 
Although cell mediated reactions are probably of greater significance, antibodies 
may have important implications for host resistance. They may be directly lytic for 
tumor cells or recruit immune cells carrying Fc receptors. In the cell mediated 
immune response two different cytolytic mechanisms can be identified. One 
involves the specific recognition of an antigen and is mediated by classical CD3/T-
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cell receptor-bearing lymphocytes that are major histocompatibility complex 
(MHC)-restricted. The other involves non-specific recognition and cytolysis, 
largely mediated by so-called natural killer (NK) cells. 
The targets for activation of the immune system are often tumor-associated 
antigens (TAA), shared by neoplastic and embryonic cells (6). Cancer is associated 
with an accumulation of mutations affecting oncogenes and growth regulating 
proteins. Recent data suggest that subtle changes, such as only one mutation in an 
oncogene can be recognized by T cells (7). In melanoma specific cytolytic T cell 
clones have been identified (8,9). Cytotoxic T lymphocytes, able to recognize 
melanoma associated antigens in a MHC-restricted manner, have recently been 
described (10). 
Cell mediated immune responses can cause destruction of certain human tumors 
in vivo (5,11,12). Some cancer patients have undergone long-lasting complete 
response following the infusion of large numbers of in vitro expanded autologous 
tumor-infiltrating lymphocytes (13). In addition, clinical responses have been seen 
in patients given monoclonal antibodies to tumor-associated antigens (14,15). A 
part of the patients, who have been immunized with preparations containing tumor 
antigens have displayed immunity to those antigens and a few of these immunized 
patients have experienced tumor regression (16-19). Therefore, if a cellular 
immune response directed against tumor cells can be demonstrated, one can wonder 
why tumors escape immune surveillance. This may be explained by a tolerance 
state or anergy, which has been reported in various models (20). This failure to 
eradicate tumor growth may also be explained by the high rate of tumor growth 
which exceeds the capacity for tumor rejection by the immune system (21). 
Activation of the immune system by administration of cytokines such as IL2 and 
IFN", may help to boost antitumor immunity. 
Interleukin-2 
IL2 is a hormone that was first described in 1976 and has been named T cell 
growth factor (22,23). It is a glycoprotein lymphokine almost exclusively produced 
by T lymphocytes of the helper subset after activation by interleukin-l derived 
from macrophages (23). IL2 acts as a pleiotropic mediator within the immune 
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system, having a variety of effects via specitic cell surface receptors. Most 
prominent is the expansion and activation of T lymphocytes, Iymphokine-activated 
killer (LAK) cells and natural killer (NK) cells (24-30). When IL2 is injected in 
vivo it leads to the production of secondary cytokines, including ILl, TNFa, 
IFNy, IL6, GM-CSF and M-CSF (31-33). These cytotoxic and antiproliferative 
cytokines may partly be responsible for the antitumor activity of IL2 (25,26,34-36). 
In animal studies IL2 mediated the regression of pulmonary and liver metastases 
from a variety of tumors (37). In mice high dose IL2 eradicated disseminated 
murine leukemia (38). Irradiated tumor-bearing mice did not respond to high doses 
of IL2, demonstrating that IL2 alone is devoid of antitumor activity in the absence 
of IL2 responsive cells (39). 
These animal data formed the basis of investigations on the role of IL2 in the 
treatment of cancer in humans. Studies have been carried out mainly in patients 
with renal cell cancer and melanoma. An overview of trials including at least 25 
patients is given in Table 1. The tirst used schedule consisted of a high dose 
intravenous bolus regimen and was developed by Rosenberg et aI., administering 
IL2 (25 MIU/m') every 8 hours for 5 days. In the initial trials impressive responses 
were seen in up to 35% of patients (40). In more recent updates and in studies 
from other groups response rates of 8-22 % for renal cell cancer and 5-24 % for 
melanoma were reported (41-49). The median survival ranged from 14 to 21 
months for renal cell cancer and 10 to 12 months for melanoma, respectively. This 
schedule, however, is associated with considerable toxicity and frequently requires 
intensive care management. Dose reductions and treatment interruptions are 
necessary in 40-50% of patients. An intermittent high-dose bolus regimen three 
times weekly yielded a response rate of 12% (50). In a randomized study of two 
bolus IL2 schedules in renal cancer a low-dose regimen (10 % of the high dose) 
reduced intensive care unit need and yet produced similar response rates (15 % 
versus 20%) (51). IL2 conjugated to polyethylene glycol (PEG) exhibits a markedly 
prolonged circulating half-life with retained biological activity. It is sufficient to 
give PEG-IL2 once a week. A regimen of initial high-dose IL2 followed by chronic 
maintenance therapy with PEG-IL2 was well tolerated and resulted in comparable 
treatment results as with high-dose IL2 alone (52). 
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TABLE 1 (studies including ~ 25 patients) 
IL2 mono therapy 
author dose-scheme nr. resp. resp. surv. ref. 
per cycle pts. rate duration in 
(%) in months 
months 
A. Renal carcinoma 
.. bolus ;, v. 
Rosenberg 720,000 IU/kg, t,l.d" d 1-5 54 22 25 NE 41 
Rosenberg 1 720,000 IU/kg, Ll.d" d 1-5 48 21 29 14 45 
Rosenberg 720,000 IU/kg, t.i,d" d 1-5 149 20 21 21 48 
Bukowski 60 MIU/m 2/d, 3 d/week 41 12 4 11 50 
McCabe 1 600,000 IU/kg, Li,d" d 1-5 37 8 NE NE 44 
Atkins2 24 MIU/m 2 , t,i.d., d 1-5 71 17 20 16 46 
Yang 720,000 IU/kg, t.i,d" d 1-5 65 20 8 NE 51 
72,000 IU/kg, t.i,d" d 1-5 60 15 8 NE 51 
Fyfe 720,000 IU/kg, Ll.d" d 1-5 255 14 20 16 49 
.. continuous j, v. 
Negrier 18 MIU/m'/d, d 1-5, 12-15 32 19 7 9 56 
Negrier 18 MIU/m'/d, d 1-5, 12-15 25 12 NE NE 59 
v.d. Maase 18 MIU/m'/d, d 1-5, 12-15 51 16 12 9 57 
Geertsen 18 MIU/m'/d, d 1-5, 12-15 30 20 NE NE 58 
Gore 18 MIU/m'/d, d 1-5, 8-12 133 14 11 11 61 
Escudier 24 MIU/m'/d, d 1-2 104 19 14 7 62 
Whitehead 6,9-13,0 MIU/m'/d, d 1-4 47 13 14 15 63 
Murray Law 1 9 MIU/m'/d, d 1-5, 13-17 34 9 11 11 64 
.. subcutaneous 
Sleyfer 9-18 MIU/m'/d, d 1-5 26 23 11 13 68 
Buter 9-18 MIU/m'/d, d 1-5 46 20 11 12 69 
B. Melanoma 
• melanoma 
Rosenberg 720,000 IU/kg, t,i,d" d 1-5 42 24 8 NE 41 
Rosenberg 1 720,000 IU/k9, Ll.d" d 1-5 22 27 7 12 52 
Rosenberg 720,000 IU/kg, Ll.d" d 1-5 134 17 14 12 48 
Parkinson 600,000 IU/kg, t.l.d" d 1-5 46 22 11 NE 42 
Whitehead 36-60 MIU/m'/d, 3 d/week 42 10 11 NE 43 
McCabe1 600,000 IU/kg, Ll.d" d 1-5 45 16 NE NE 44 
Sparano2 6,0 MIU!m2 , t,Ld" d 1-5 44 5 12 10 47 
* continuous i. v. 
Dorval 16-24 MIU/m'/d, d 1-3/5 37 22 NE NE 60 
legha 12 MIU/m'/d, d 1-4 33 22 6 10 65 
t.i.d '" three times per day 
NE '" not evaluated 
MIU '" 105 1U , 
= randomized triallL2 versus IL2/LAK 
= randomized triallL2 versus IL211FNa 
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Early studies suggested that IL2 by continuous instead of bolus infusion could 
yield good antitumor activity with decreased toxicity (53,54). However, a randomi-
zed study comparing continuous infusion and bolus injections at equivalent doses 
found similar toxicity (55). Several trials using continuous i.v. IL2 in dosages of 7-
24 MIU/m'/day have shown response rates of 9-20% in renal carcinoma and 17-
22 % in melanoma (56-65). 
In order to simplify IL2 therapy and to reduce toxicity, several investigators 
attempted to utilize the subcutaneous administration route. This treatment can 
generally be given on a outpatient basis. The side effects are usually mild to 
moderate (66-69). Antitumor effects are difficult to interpret, because most studies 
are small phase I-II trials. The only study including a sufficient number of patients 
reported a response rate of 20% in renal cancer (69). The use of small amounts of 
natural IL2 by inhalation has been suggested as a non-toxic local treatment of 
pulmonary metastases (70). 
Overall, IL2 induces objective responses in 15-20% of patients with metastatic 
renal carcinoma and melanoma without signitlcant differences according to route, 
schedule and dosage. Patients with a prolonged disease-free interval, good perfor-
mance status and a limited number of sites of disease are more likely to have a 
response (71,72). IL2 may offer a survival benefit to responding patients, especial-
ly those with a complete remission are reported to have a long progression-free and 
overall survival (48). In one study IL2 treated patients showed a longer survival 
than patients who received chemotherapy (72). 
The administration of IL2 has also been investigated in other solid tumors such 
as carcinoma of colon, breast, lung, ovary, bladder, pancreas, and head and neck. 
All studies included only small numbers of patients. In general, the reported 
response rates are low « 10%), durations of response are short « 6 months) and 
the effects on survival not demonstrable or not reported (40,41,73-75). 
IL2-related toxicity 
The toxicity of IL2 administration can involve virtually every organ system. A 
vascular leak syndrome (VLS) appears to be an important underlying mechanism. 
The increase in vascular permeability causes an egress of intravascular fluid into 
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the interstitium with edema, weight gain, pleural effusions and ascites. The 
similarities between the major IL2 associated toxicities, i.e. VLS and hypotension 
and the features of septic shock suggest that the underlying systemic activation of 
inflammatory mediator systems (complement, coagulation and fibrinolytic systems), 
culminating in endothelial damage is a common factor. The principal cytokines 
thought to be involved include TNFa and ILl, produced as part of the cytokine 
cascade (76-78). Corticosteroids reverse most adverse effects but also eliminate 
antitumor activity (79-81). 
Cardiovascular toxicity consists of hypotension, tachycardia, decreased vascular 
resistence and decreased ejection fraction (82-86). In general, a weight gain of up 
to 10-20% can occur. With high-dose schedules hypotension is often dose limiting 
and the use of vasopressors is needed in up to 50-70% of patients (40,53,82-87). 
Other reported cardiac toxicities are ventricular and supraventricular arrhythmias, 
ischemia, myocardial infarction and cardiomyopathy (82-90). 
Another manifestation of VLS is pulmonary edema, leading to abnormalities in 
gas exchange, hypoxemia, and increase in total lung water (83,84,86,91,92). 
Pleural effusions may also contribute to respiratory distress. Renal dysfunction is 
manifested by azotemia, oliguria, low sodium excretion and elevated renin activity 
(85,86,93-96). Prerenal hypoperfusion of the kidneys is mainly responsible for 
renal dysfunction, but a direct toxic effect of IL2 on the kidneys can not be 
excluded (97). 
Gastrointestin,al toxicities include anorexia, xerostomia, glossitis, stomatItls, 
nausea, vomiting and diarrhea (85,86,98,99). Elevations in liver function tests are 
almost always seen and reversible cholestasis is common (100,101). Possible 
manifestations of neuropsychiatric toxicity are agitation, forgetfulness, confusion, 
hallucinations, and occasionally seizures or coma (86,102-104). 
Other toxicities frequently seen with IL2 therapy include chills, fever, flu-like 
symptoms and fatigue. Cutaneous manifestations are macular erythema, burning, 
pruritis and desquamation (98,105). Anemia, thrombocytopenia and thyroid 
function abnormalities occur relatively frequently (106-111). There is an increased 
incidence of bacterial infections (112,113). 
In general IL2 related toxicities will begin to reverse within 24 hours of 
cessation of treatment with complete resolution usually within a few days to a 
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week. Most adverse effects are predominantly associated with the application of 
intermediate to high-dose regimens. Outpatient therapy with subcutaneous IL2 is 
associated with moderate toxicities such as fever, chills, fatigue, skin changes, 
diarrhea, nausea, vomiting, stomatitis and irritation at the injection site. 
Interferon-alpha 
In 1957 the interferons were first described as a group of proteins, produced by 
cells in response to virus infections (114). Now it is known that they playa key 
role in host responses by modulating immune cell function. IFNs are classified into 
IFNa, IFN{3 and IFN'Y. Interferon-alpha has antiproliferative and direct cytostatic 
effects on tumor cells (115-117). It upregulates the expression of MHC class I and 
II, (3-microglobulin as well as tumor associated antigens (115,116,118,119). The 
stimulated expression of tumor antigens may make neoplastic cells more susceptible 
to cytotoxicity by immune T cells of the host. 
IFN", also has the ability to stimulate the activation of mature NK cells and to 
promote their differentiation from precursors (116). Stimulation of NK cells may 
result in lysis of tumor cells. The development of cytotoxic T lymphocytes, 
monocytes and macrophages is supported by interferon-alpha (116,117,119). 
After the demonstration of the antitumor activity of IFNa in various mouse 
models (120), the administration in patients was studied. In metastatic renal 
carcinoma response rates varied from 5 to 27% with an average of 15% (121-128). 
The median duration of response and survival were approximately 6 and II 
months, respectively. The adminstered dosages ranged between 3 and 36 
MU/m'/day. There does not appear to be a dose-response relationsbip for IFNa, 
albeit that a certain threshold of 3 MU/m'1 day seems necessary to induce respon-
ses (127,128). Responses occur predominantly in patients with good performance 
status, prior nephrectomy and limited metastatic disease, particularly when confined 
to the lung. A study comparing patients treated with IFN", with chemotherapy 
suggested a survival benefit for the cytokine group (129). 
The overall response rate of IFN", in metastatic melanoma is about 16% (range 
6-27%) with approximately one-third complete remissions (130-135). The median 
duration of remission is 4-6 months, however complete responses of several years 
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have been reported. Survival is mostly very short (6 months). The best therapeutic 
results in melanoma have been achieved with uninterrupted schedules, regardless of 
route. There is no clear advantage of lower or higher dosages of IFNC\' in the range 
between JO and 50 MU/m'/day (135). Patients with a lower performance status or 
visceral metastases have a reduced response rate. 
Several well-described side effects are ubiquitous after first exposure to IFNC\'. 
A flu-like syndrome with fever, chills, headache, malaise, myalgias, arthralgias, 
and fatigue occurs in the majority of patients and diminishes over time with 
continued administration (135,136). Long-term toxicity consists of anorexia, weight 
loss and fatigue. The latter symptom is often dose-limiting. Neuropsychiatric 
adverse effects are somnolence, lethargy, overall mental and motor slowing and 
confusion (135,136). Frank depression and psychosis are rare events and occur 
mostly with the high dose regimens. The most important hematological toxicity is 
leUkopenia with a decrease in both granulocyte and lymphocyte counts (135,136). 
These changes are caused by a redistribution of circulating leucocytes, rather than 
by true myelosuppression. Anemia and thrombocytopenia occur less frequently. 
Gastrointestinal toxicity consists of anorexia, aberrant taste, nausea, vomiting, 
and diarrhea. Diarrhea can be severe at high doses (136). Elevation of transaminase 
levels is observed in 30% of patients, although the incidence is higher at high doses 
(136). Effects on the cardiovascular system and renal function are less common 
with IFNC\'. Symptoms such as tachycardia, rythm disturbances, vasoconstriction 
and hypotension may be directly related to the febrile reaction. Nonetheless, 
caution must be used in patients with a history of ischemic heart disease. The most 
common renal toxicity is proteinuria, occurring in approximately 15% of patients 
(136). 
IL2 and IFNU' 
Since the mechanisms of action of IL2 and IFNC\' are partly different, it can be 
expected that the combination of these cytokines may act additively or even 
synergistically. Experimental data from a variety of animal tumor models showed 
that the combined administration of IL2 and IFN", mediated greater therapeutic 
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effects against established subcutaneous, hepatic and pulmonary metastases than 
either agent delivered alone (137-139). 
In renal cancer and melanoma many clinical trials have been carried out, using 
a great variety of doses and routes of administration (Table 2). The reported 
response rates showed a wide range, varying from 0 to 40% (140-156). The NCI 
Surgery Branch undertook a phase I dose escalating study administering bolus 
injections of IL2 and IFN" (140). In the highest dose regimens response rates of 
38% for renal carcinoma and 43% for melanoma were observed. However, a high 
incidence of severe toxicities forced the investigators to modify the treatment 
schedule and to select a lower dose level (151). Especially cardiac and central 
nervous system toxicity were dose-limiting. The response rates decreased to 25 % 
with the modified dose schedule. A Dutch study, trying to confirm the initial 
encouraging response rate of the NCI trial, observed a similar drop in treatment 
results from 41 % to 20% after modification of the dose, which was necessitated by 
the associated severe toxicity of the high dose schedule (90,156). 
Schedules administering IL2 continuous Lv. in intermediate to high doses 
yielded response rates of 7-33% for renal cell cancer and 10-29% for melanoma, 
respectively (141-145,149,152,155). The demonstrated median survival varied 
between 10 and 21 months. The differences in treatment results are difficult to 
interpret due to the wide variation in schedule and dosage. Keilholz et a!., using a 
decrescendo schedule of initial high dose IL2, subsequently tapered to a lower 
maintenance dose reached a high response rate of 41 % in melanoma (149). 
However, the study was small and no confirmation trials have been performed. 
Two studies in patients with renal carcinoma have been carried out adminis-
tering the most intensive regimen of immunotherapy reported safar, consisting of 
the combination of high-dose IL2, IFN" and Iymphokine-activated killer cells 
(LAK) (157,158). Response rates of 24% and 39%, respectively, were achieved. 
However, the associated toxicity was considerable with several toxic deaths, and 
the patients could tolerate only 40-50% of the planned dose of cytokines. 
A limited number of randomized trials have been done comparing the efficacy 
of the combination of IFN" and high-dose IL2 versus IL2 alone (46,47). Combined 
treatment appeared not to achieve superior results. In renal cancer response rates of 
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17% for IL2 alone and 11 % for the combination were reported (46). In melanoma 
responses were seen in 5% and 10% of patients, respectively (47). 
TABLE 2 (studies including 2: 25 patients) 
Il2 + IFNa 
author dose-scheme nr. resp. resp. surv. ref. 
per cycle pts. rate duration in 
(%) in months 
months 
A. Renal carcinoma 
* bolus i. v. 
Rosenberg IL2 2.6-11.7 MIUlm 2 , t.Ld., d 1-5 35 31 10 NE 140 
IFN 3·6 MIU/m', '.i.d" d 1-5 
Bergmann IL2 18 MIU/m'/d, o.d.d., d 1·14 35 26 10 NE 146 
IFN 10 MIU/m'/d, o.d.d" d 1-14 
Atkinsl IL2 14.4 MIU/m', Li.d., d 1-5 28 11 NE 16 46 
IFN 3 MIU/m 2, Li.d., d 1-5 
Marincola 2 IL2 2.6-15.6 MIU/m', Li.d., d 1-5 75 28 37 31 151 
IFN 3·6 MIU/m', t.i.d" d 1-5 
Negrier3 IL2 24 MtU/m2, t.Ld., d 8-12, 19-23 29 24 6 8 157 
IFN 20 MIU/m'/d, d 1-5 
IFN 5 MIU/m', Li.d" d 8-12, 19-23 
* continuous i. v. 
IIson IL2 7 MIU/m'/d, d 1-4 34 12 NE 11 141 
IFN 5 MIU/m'/d, d 1-4 
Figlin IL2 4.5 MIU/m'/d, d 1-4 30 30 12 12 142 
IFN 6 MIU/m'/d, d 1-4 
Sznot IL2 7-14 MIU/m'/d, d 1-5, 11-16 40 20 8 NE 143 
IFN 12 MIUlm 2 /d, 3 d/week 
Oldham IL2 18 MIU/m'/d, d 1-5 83 7 3 11 144 
IFN 3 MIU/m'/d, d 1,3,5 
Lipton IL2 2.3-9.2 MIU/m'/d, d 1-4/5 39 33 15 21 145 
IFN 3-12 MIUlm1/d, 2-3 d/week 
Stoter3 IL2 18 MIU/d, d 1-5, 12-16 41 39 14 15 158 
IFN 5 MIU/d, d 1-5, 12-15 
• subcutaneous 
Vogelzang IL2 12 MIU/d, d 1-4 42 12 NE 15 147 
IFN 9 MIU/d, d 1 + 4 
Ravaud IL2 18 MIU/m'/d, d 1 + 2 38 18 7 8 150 
IL2 3.6 MIU/m 2/d, 5 d/week, sq 
IFN 5 MIU/m'/d, 3 d/week 
Facendola IL2 9 MIU/m'/d, d 1 + 2 50 18 12 12 153 
IL2 1.8 MIU/m', b.i.d., 5 d/week 
IFN 5 MIU/m'/d, d 1,3,5 
Atzpodien4 IL2 5-20 MIU/m'/d, 3 d/week 152 25 NE NE 154 
IFN 6-9 MIU/m'/d, 1-3/week 
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author dose-scheme nr. resp, resp, surv, 
per cycle pts, rate duration in 
(0/0) in months 
months 
B. Melanoma 
* bolus i. v. 
Rosenberg IL2 1-4.5 MIU/m', t.i.d., d 1-5 39 33 7 NE 
IFN 3-6 MIU/m 2, t.i.d., d 1-5 
Sparano1 IL2 4.5 MIUlm2 , t.i.d" d 1-5 41 10 12 10 
IFN 3,0 MIU/m', t.i.d., d 1-5 
Marincola2 IL2 2.6-15.6 MIU/m', t.i.d., d 1-5 82 24 10 20 
IFN 3.0-6.0 MIU/m2 , t.Ld., d 1-5 
Kruit IL2 4.5 MIU/m', t.l.d., d 1-3/5 42 29 7 9 
IFN 3,0 MIU/m', t.l.d., d 1-3/5 
.. continuous i. v. 
Oldham IL2 18 MIU/m'/d, d 1-5 66 10 2 10 
IFN 3 MIU/m'/d, d 1,3,5 
Keilholz IL2 18 MIU/m'/d, d 8-12 27 18 6 11 
IFN 10 MIU/m'/d, d 1-5 
Keilholz IL2 18 MIU/m'/6-24 h, d 8-12 27 41 11 NR 
IFN 10 MIU/m'/d, d 1-5 
Kruit IL2 7.8 MIU/m'/d, d 1-4 51 16 8 11 
IFN 6 MIU/m'/d, d 1 + 4 
b.Ld. 0= two times per day 
o.d.d. '" every other day 
U.d. = three times per day 
NE '" not evaluated 
NR = not reached 
~q = sequential 
"" randomized trial IL2 versus IL2/IFNa 
= one patient cohort received IFNa 6 MIUfm2/day 
= also treatment with LAK 
= some patients also received 5·FU 750 mg!m2/week 
The subcutaneous administration of IL2 combined with IFN", as an outpatient 
treatment has also been explored, especially in renal cancer. The reported response 
rates ranged from 12-25% (147,150,153,154). The median survival with the 
subcutaneous route seemed to be somewhat shorter than with intravenous administ-
ration. 
In other solid tumors experience with the combination of IL2 and IFN", is very 
limited. A few studies have been done in breast and head and neck cancer, but 
patient numbers are insufficient to draw conclusions (75,159). 
In conclusion, the addition of IFNa to IL2 has not meaningfully improved the 
treatment results in comparison with monotherapy with IL2 alone. The combination 
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of high-dose bolus IL2 and IFN", may have a somewhat higher response rate. 
However, it is doubtful whether this can be translated into a survival benefit. The 
accompanied severe toxicity remains a serious problem. 
IL2 and chemotherapy 
Metastatic renal cell carcinoma and melanoma are poorly sensitive to chemo-
therapeutic agents and as yet no standard chemotherapy has been established (160, 
161). The combination of chemo- and immunotherapy may be a new therapeutic 
approach. In an animal model the administration of cyclophosphamide prior to IL2 
resulted in improved response of lung metastases (162). Similar results have been 
observed in other models with the use of chemo-immunotherapy (163,164). Based 
on these preclinical data several studies in humans have been carried out, especially 
in melanoma. A summary of the most important trials is given in Table 3. There 
was some concern that cytostatics may impair the stimulatory effects of IL2. 
However, no obvious impairment of IL2 induced immune mechanisms has been 
detected (165). 
In renal cancer the combination of IL2 and cyclophosphamide showed disap-
pointing results with only incidental partial responses (166-168). An outpatient 
three-drug combination regimen consisting of IL2 and IFN", subcutaneously with 5-
fluorouracil yielded an objective response rate of 49% (169). Systemic toxicity was 
mild to moderate. 
In melanoma dacarbazine (OTIC) has been the most commonly used chemothe-
rapeutic agent in combination with IL2. Response rates of 16-26% with a median 
survival of 9-13 months has been observed (170-173). Cisplatin (COOP) alone or 
combined with OTIC added to IL2 resulted in response rates of approximately 40% 
(174-176). Recently, more aggressive multi-agent combinations of chemo-immuno-
therapy have been developed. Intensive regimens consisting of IL2 and IFN", in 
combination with COOP (177), or COOP, OTIC and carmustine (178,179), or 
COOP, OTIC and vinblastine (180) or OTIC and carboplatin (179,181) yielded 
relatively high response rates of 35-57 %. The preliminary survival data show a 
median duration of about 10 months. 
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TABLE 3 (studies including ~ 25 patients) 
Chema-immunotherapy in melanoma 
author scheme per cycle number response response survival 
of rate (%) duration (months) 
patients in months 
Flaherty IL2/DTIC 32 22 5 9 
Dillman IL2/LAK/DTIC 27 26 4 10 
Stoter IL2/DTIC 25 24 7 13 
Dummer IL2/DTIC 57 16 14 9 
Demchak IL2/CDDP 27 37 4 NE 
Flaherty IL2/CDDP/DTIC 32 41 8 10 
Atkins IL2/DTIC/CDDP/Tam 38 42 6 11 
Khayat IL2/1FNalCDDP 39 54 6 11 
Richards IL2/1FNaiDTIC/CDDP/BCNUITam 42 57 8 12 
Atzpodien IL2/DTIC/IFNaICarbo 40 35 8-19 NE 
Atzpodien IL2/1FNaiDTIC/BCNU/Tam 27 56 7-11 NE 
Legha IL2/1FNaIDTIC/CDDPlVin 60 53 NE NE 
NE '" not evaluated 
OTIC = dacarbazine 
COOP '" cisplatin 
BCNU = carmustine 
Carbo = carboplatin 
Yin = vinblastin 
T,m '" tamoxifen 
The role of ILl in combination with 5-fluorouracil (5-FU) or with 5-FU and 
leucovorin (LV) has been studied in colorectal cancer. In small phase I and II 
studies response rates of approximately 30% have been reported (74). However, a 
randomized trial comparing IL2 by continuous infusion in combination with 5-FU 
and LV versus 5-FU and LV alone did not show differences in response rates (17% 
vs 16%) (182). 
In conclusion, although these studies suggest that chemo-immunotherapy results 
in better response rates than either modality alone, especially in patients with 
melanoma, there is no clear proof that response duration is improved. The demon-
stration of eventual survival benefit requires phase III trials. 
IL2 and effector cells 
As previously mentioned IL2 induces the expansion and activation of non-
specific lymphokine-activated killer cell activity (LAK). These LAK cells are 
predominantly NK cells. Preclinical animal studies showed that the combination of 
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LAK cells and IL2 markedly improved antitumor activity (162,183). In vitro 
studies have also shown that tumors of many different histological types are 
susceptible to lysis by human LAK cells (26). 
As a rule, patients are given IL2 for 3-5 days to increase the number of 
circulating LAK cell precursors. Subsequently, these precursors are harvested by 
apheresis and incubated in vitro with IL2 to generate LAK cells. These effector 
cells are reinfused into the patient over a period of 3-4 days with concurrent IL2 
administration. 
The overall experience with IL2 and LAK cells showed response rates varying 
from 3-35% (Table 4) (40,41,44,45,55,56,64,159,184-189). Studies using high-
dose bolus IL2 (25 MIU/m' every 8 hours) reported response rates of 13-35% in 
metastatic renal cancer and 12-22 % in melanoma (40,41,44,45,55,184,185). Treat-
ment schedules of continuous i. v. IL2 (9-18 MIU/m'/day) resulted in response rates 
of 3-27% and 3-23 %, respectively (55,56,64,159,186-189). Data about survival 
and response duration are limited. Median survival durations ranged between 9 and 
20 months for renal cancer and 6 and 11 months for melanoma (45,55,56,64, 
159,187,189). The contention is that combined treatment with IL2 and LAK does 
not increase the side effects as compared to IL2 alone. 
It is important to determine in a randomized fashion whether the addition of 
LAK cells offers improved therapeutic benefit. Until now 3 randomized trials have 
been carried out (44,45,64). None showed a higher response rate or longer survival 
for the LAK arm, neither in renal cancer nor in melanoma. In one study there was 
a trend toward more complete responses in patients treated with the combined 
modality (45). In conclusion, in renal cell cancer as well as in melanoma, the 
combination of IL2 plus LAK has not yielded superior treatment results compared 
to IL2 alone. Also in other solid tumors there is no indication that the addition of 
LAK has improved the response rates (41,75,159). 
An other population of cytolytic lymphocytes, that can be used as effector cells 
in combination with IL2, are tumor-infiltrating lymphocytes (TIL). These T 
lymphocytes are found within solid tumors. Unlike non-specific LAK cells, TILs 
are able to recognize tumor-associated antigens in a specific MHC-restricted 
manner (190,191). TILs are capable of mediating cytotoxic activity against 
autologous and allogeneic tumor targets in vitro (192,193). In the presence of IL2, 
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TILs can be activated and expanded to great numbers in cultures of several weeks. 
The adoptive transfer of TILs plus IL2 to tumor-bearing animals appeared to be 50-
100 times more effective than LAK cells plus IL2 (190,191,194). 
TABLE 4 (studies including 2. 25 patients) 
IL2 + LAK 
author scheme nr. resp. resp. surv, ref. 
per cycle pts, rate duration in 
(%) in months 
months 
A. Renal carcinoma 
~ bolus i. v. 
Rosenberg 720,000 IU/kg, t.i.d .. d 1-5, 11-15 36 33 NE NE 40 
Rosenberg 720,000 IU/kg, t.i.d .. d 1-5, 11-15 72 35 11 NE 41 
Rosenberg 1 720,000 IU/kg, t.i.d .. d 1-5, 11-15 49 31 13 20 45 
Fisher 600,000 IU/kg, t.i.d., d 1-5, 12-16 32 16 12 NE 184 
McCabe! 600,000 IU/kg, t.i.d., d 1-5, 11-15 30 13 NE NE 44 
Weiss 600,000 IU/kg, t.i.d., d 1-5, 11-15 46 20 NE NE 55 
* continuous j, v. 
Negrier 18 MIU/m'/d, d 1-5, 12-15 51 27 6 13 56 
Parkinson 600,000 IU/kg, t.i.d., d 1-3, 44 9 NE NE 187 
18 MIU/m'/d, d 9-14 
Thompson 14 MIU/m'/d, d 1-5, 42 33 5-18 NE 189 
4.6-14 MIU/m'/d, 12-16 
Weiss 18 MIU/m'/d, d 1-5, 48 15 NE NE 55 
22.5 MIU/m'/d, d 11-16 
Dillman 18 MIU/m'/d, d 1-5, 11-15 46 15 7 9 159 
Murray law l 9 MIU/m'/d, d 1-5, 13-17 35 3 NE 13 64 
B. Melanoma 
.. bolus i,v. 
Rosenberg 720,000 IU/kg, t.i.d., d 1-5, 11-15 48 21 6 NE 40 
Rosenberg 1 720,000 IU/kg, t.i.d., d 1-5, 11-15 27 22 42 11 45 
Dutcher 600,000 IU/kg, t.i.d., d 1-5, 11-15 32 19 5 NE 185 
McCabe1 600,000 IU/kg, t.i.d., d 1-5, 11-15 49 12 NE NE 44 
• continuous i. v. 
Bar 600,000 IU/kg, t.i.d., d 1-3 50 14 21 NE 186 
18 MIU/m'/d, d 9-15 
Dutcher 18 MIU/m'/d, d 1-5 33 3 NE NE 18B 
22.5 MIU/m'/d, d 11-15 
Dillman 18 MIU/m'/d, d 1-5,11-15 53 23 4 6 159 
t.i.d. = three times per day 
NE = not evaluated 
MIU '" 106 1U , 
= randomized triallL2 versus IL2/LAK 
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These murine studies led to clinical trials with TILs and IL2 demonstrating 
regression of metastatic disease in patients with renal cell cancer and melanoma. 
The best treatment results have been shown in metastatic melanoma with response 
rates of 19-34 %, whereas in renal cell carcinoma responses have been rare 
(13,159,195-199). TILs with MHC-restricted specificity to the autologous tumor 
have predominantly been demonstrated in melanoma (198). In other tumors the 
existence of MHC-restricted TILs is equivocal. The rather disappointing clinical 
results may be explained by lack of tumor specific recognition by TILs or inhibiti-
on of their lytic capacities by immunosuppressive factors produced at the tumor site 
(200). Additionally, in spite of earlier suggestions, preferential traflicking of TILs 
to tumor deposits could not be confirmed (201,202). Further important limitations 
of TIL therapy are the labor-intensive laboratory procedures and the limited 
number of patients from whom tumor specific TILs can be isolated. 
Tumor targeting 
New strategies for the improvement of adoptive immunotherapy focus on 
targeting immune cells to tumor cells (203). One attempt to improve treatment 
emcacy is the development of gene moditled TILs. TILs can be transduced with 
several cytokine genes, which dictates the delivery of increased amounts of 
cytokines such as IL2, IL4, TNFc<, IFNI' and GM-CSF at the tumor site. In this 
way transfected TILs can enhance the local antitumor effects. Several studies have 
demonstrated that gene transduction can he successfully carried out in autologous 
TILs of patients without altering their properties (201,204,205). However, given 
the above mentioned restrictions associated with TILs, it is diflicult to foresee a 
more fruitful clinical application of this therapeutic approach. 
The concept that T cells can be activated and targeted to tumor cells by either 
bispecillc monoclonal antibodies (BsMAbs) or by genetic modification of the T cell 
receptor is under intensive scrutiny. BsMAbs are hybrid antibodies constructed 
from two parent MAbs: one specitle for the immune effector cell, e.g. the 
CD3/TCR complex and the other specific for a tumor-associated antigen on the 
target cell (206-209). BsMAb-mediated cross-linking of the effector T cell to the 
tumor target cell via specific cytotoxic trigger molecules results in activation of the 
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lymphocyte lytic machinery and destruction of the tumor target in vitro and in vivo 
(207,208,210-213). BsMAbs can also be used to target and activate monocytes, 
macrophages, NK cells and neutrophils (209,214,215). The advantage of the use of 
BsMAbs is that all cytotoxic T lymphocytes regardless of their TCR specificity can 
be redirected and activated to lyse tumor cells, provided that these cells express 
tumor-associated antigens. 
In pilot studies in patients with ovarian cancer and glioma, proof of concept 
was demonstrated since antitumor responses were indeed observed (216,217). In 
these studies, BsMAb-coated T cells were given locoregionally. The systemic 
administration of BsMAbs has also been investigated in phase I studies in renal cell 
cancer, ovarian cancer and breast cancer (218-222). The observed toxicities 
comprise fever, chills, nausea, vomiting, dyspnea, hypotension and anaphylactic 
reactions at low doses, indicating that this route of administration may be not very 
suitable for clinical use (218,220). In addition, the use of BsMAbs has other 
limitations. BsMAb-targeted lymphocytes only retain their antibody-dictated 
specificity for a short period of time (48-96 h), due to dissociation of BsMAb 
from the cell surface (203,208,223). More-over, BsMAb redirected lymphocytes 
can lose their signal transducing and lytic capacity (223). It is unknown whether 
systemically administered BsMAb redirected immune cells can migrate from the 
blood circulation to the tumor site (203). Thus, BsMAbs may be most effective 
when applied locoregionally. 
To circumvent the limitations associated with BsMAbs and to achieve long-
lasting and systemic immune responses a novel approach has been developed, in 
which T lymphocytes are modified by molecular engineering with a permanent 
antibody-dictated specificity (224-228). This technique is based on the construction 
of a chimeric immunoglobulin-T cell receptor (Ig-TCR) with a laboratory chosen 
tumor-associated antibody gene. To become effective, these lymphocytes require 
the expression of the engineered Ig-TCR on their surface, in association with the 
CD3 signal transducing complex. This was achieved by the construction of 
chimeric Jg-TCR genes in which the variable segments of the TCR genes were 
replaced by the variable segments of an immunoglobulin gene with known specifi-
city (224-228). 
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It has been demonstrated that chimeric Ig-TCR genes can be transduced into T 
lymphocytes, resulting in the functional expression of the chimeric receptors on 
their cell surface. Stimulation of the chimeric receptor results in T cell activation, 
cytokine production and lysis of target cells (227-231). In contrast to BsMAb 
redirected lymphocytes, who lose their lytic capacity, lymphocytes transduced with 
chimeric Ig-TCR genes show recycling of the cytolytic process (223,231). An 
important feature of Ig-TCR lymphocytes is that they recognize tumor-associated 
antigens in a MHC-unrestricted manner. Hence their antitumor activity is not 
adversely affected by tumor cells, which downregulate their MHC complex or do 
not adequately express antigens in the groove of the MHC complex (232). Studies 
in patients, using this promising treatment approach are in preparation. 
Other methods of improving tumor targeting focus on ways to mimick tumor 
immunogenicity by vaccination. It has been demonstrated that cytokine genes can 
successfully be introduced into tumor cells. Experimental studies have shown that 
genetically modified tumor cells expressing cytokines such as IL2, lIA, IL6, IFNy, 
or GM-CSF were capable of inducing immune responses (233-237). Tumor cells 
engineered with cytokine genes act as self-replicating minipumps secreting increa-
sed amounts of that particular cytokine. Vaccination experiments in tumor bearing 
animals showed localized secretion of cytokines which mediated tumor rejection 
(238-240). Neoplastic cells transduced with the IL2 gene were able to generate 
specific cytotoxic lymphocytes with memory against subsequent tumor challenges 
(233,234,240). Further experiments demonstrated that human tumor cells can also 
be engineered with cytokine genes (241-244). On the basis of these findings pilot 
studies of cytokine transfer by vaccination with irradiated allogeneic tumor cells in 
patients with malignant tumors have been started (245,246). 
Immunization efforts are also focused on the development of antigen-based 
vaccines to activate silent precursor cytotoxic lymphocytes. Thus far, a number of 
antigens have been identified as largets for recognition by cytotoxic lymphocytes, 
mostly in melanoma (MAGE, Melan A/MART, tyrosinase, gp 100), but also in 
other tumors (HER2/neu, p2lras) (10,247-253). These antigen peptide epitopes are 
recognized by T cells in the context of MHC class I or II molecules. The first 
experience with vaccination with these immunogenic peptides in humans demon-
strated antigen-specific delayed type hypersensitivity reactions and an increase of 
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antigen-specific cytotoxic lymphocyte reactivity (254,255). Besides pruritis and skin 
induration at the injection site no significant adverse effects were observed. It is too 
early to draw conclusions about possible antitumor effects, but it appears that this 
vaccination strategy may be most appropriate as adjuvant therapy after resection of 
the primary tumor or in patients with a low tumor load. Vaccination with whole 
proteins containing multiple antigenic epitopes may increase the chance of multidi-
rectional T cell activation (256). 
Conclusions 
Adoptive immunotherapy with cytokines such as IL2 and IFN" with or without 
the use of MHC-unrestricted effector cells yields good results in a small proportion 
of patients, almost exclusively with metastatic renal cell cancer and melanoma. 
Tumor responses occur in 10-25% of patients with 5-10% complete responses. 
Especially the complete responders can have durable responses and survival 
benefit. Higher dose regimens do not improve the treatment results but do increase 
the toxicity. Chemo-immunotherapy, especially in melanoma patients, may be more 
promising than either modality when used alone, since several studies reported 
encouraging response rates. However, as yet, no randomized trials have been 
carried out. 
For improvement of these treatment results a tumor-specific or tumor-targeted 
immunotherapy strategy is essential. The use of tumor-infiltrating lymphocytes as 
possible specific MHC-restricted effector cells has clearly demonstrated antitumor 
effects. However, except in melanoma, TILs appear to lack sufficient specificity to 
be of great importance in the treatment of other cancers. Whether engineered TILs, 
tranduced with cytokine genes, are endowed with a better specillcity and give 
improved results has to be awaited. 
The concept of redirecting lymphocytes towards tumor cells using bispecific 
monoclonal antibodies is an attractive treatment approach. The advantage is that all 
T lymphocytes may be activated irrespective of the specificity of their receptor. 
However, it is unlikely that BsMAb redirected immune cells can be used systemi-
cally because of the anaphylactoid reactions observed. 
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More interesting is the development of the chimeric Ig-TCR receptor with its 
MHC-unrestricted tumor selective recognition features. This treatment modality has 
not yet reached the clinic. 
Finally vaccination studies with cytokine transduced tumor cells or with 
antigenic peptides/proteins has demonstrated the possibility of inducing tumor-
specific cytotoxic lymphocytes. This opens perspectives for the composition and 
application of antigen-specific cancer therapy. 
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Summary 
The cytokines interleukin-2 (lL2) and interferon-alpha (IFNa) have several 
inullunomodulatory and antitumor effects. Immunotherapy with these two 
cytokines, administered as single agents, has demonstrated activity against 
metastatic renal cell cancer and melanoma. Based on preclinical evidence and initial 
treatment results of phase I studies, has it been suggested that the combination of 
IL2 and IFNa has a better antitumor effect than either cytokine alone. This thesis 
describes the results of several phase II studies of IL2 and IFNa in patients with 
metastatic renal cell carcinoma and melanoma. 
Chapter 1 gives a short overview of the most important immunomodulatory 
and antiproliferative effects of IL2 and IFNiX. The results of clinical studies with 
monotherapy of IL2 or IFNiX are summarized. The rationale for combining IL2 and 
IFNa in the treatment of cancer is described. 
In Chapter 2 our initial experience with the combined use of IL2 and IFNa in 
two different schedules in patients with metastatic melanoma is presented. The 
preliminary response rates of these two studies were 21 % and 56%, respectively. 
The final analysis of a multicenter phase II study in patients with metastatic 
melanoma is reported in Chapter 3. Patients were treated with IL2 7.8 
MIU/m'/day for 4 days by continuous infusion and IFNa 6 MU/m'lday, day 1 +4 
subcutaneously. Fifty-one patients were evaluable for response and toxicity. Eight 
of them (16%) obtained an objective response, one complete (2%) and 7 partial 
(14 %). The median duration of response and thc median survival were 8 and 11 
months respectively. Common side effects included fever, chills, fatigue, skin rash, 
nausea, vomiting and diarrhea. It was concluded that this regimen of IL2 and IFNiX 
in an intermediate dose intensity was only moderately active and not superior to 
IL2 alone. 
In Chapter 4 the results of two schedules of high-dose bolus administration of 
IL2 and IFNa in metastatic melanoma are presented. Patients were planned to 
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receive IL2 11.7 MIU/m' and IFN", 3 MU/m' by intravenous bolus administration 
every 8 hours for a total of 3 cycles. In the first schedule treatment duration was 5 
days per cycle. Of the 17 evaluable patients, 2 (12 %) achieved a complete and 5 
(29%) a partial response (overall response rate 41 %). This part of the study was 
closed prematurely due to the occurrence of severe cardiotoxicity (41 %) and central 
nervous system toxicity (28 %). In the second schedule the same dosages of 
cytokines were administered, however for 3 instead of 5 days per cycle. In the 
second part of the study 5 of the 25 evaluable patients responded (20%, only 
partial responses). The associated adverse effects were manageahle. It was 
concluded that this 5-day schedule of high-dose IL2 and IFN"" although it had a 
relatively high response rate, was accompanied by unacceptable toxicity. The 
modified 3-day schedule gave treatment results not better than with IL2 monothe-
rapy. 
The results of single center study with an immunotherapy regimen consisting of 
IL2, IFN", and Iymphokine-activated killer (LAK) cells in patients with metastatic 
renal cell cancer are reported in Chapter 5. Seventy-two patients were included, 
17 in a feasibility part (protocol 1) and 55 in an efficacy part (protocol 2). 
Treatment consisted of IL2 18 MIU/m'/day, day 1-5 and 12-15 hy continuous 
infusion and IFN", 5 MIU/m'/day, day 12-15 intramuscularly. LAK infusions were 
given on day 12-14. In protocol 2 IFN", was also administered on day 1-5. Each 
patient was planned to receive two induction cycles. Patients, whose disease 
stabilized or responded, received maintenance therapy with the same dose regimen 
of IL2 and IFN", during 4 days every 4 weeks up to a total of 4 cycles. Of the 
patients in protocol 1, 3 achieved a complete and one a partial response (overall 
response rate 24%). The median duration of response and the median survival were 
18 and 14 months, respectively. Toxicity was manageable and no dose reductions 
were necessary. In protocol 2 response rate was 37%, 6 complete and 13 partial 
remissions. The median response duration and the median survival were 11 and 17 
months, respectively. Toxicity was considerable with three treatment related deaths. 
In protocol 2 only approximately 40-50% of the planned doses could be 
administered. It was concluded that the use of high-dose schedules of IL2 and 
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IFN", is not warranted, unless we can define more accurately the subgroup of 
patients who will experience long-term survival as a result of this treatment. 
Chapter 6 gives a detailed description of several cases of severe cardiotoxicity 
observed in a subgroup of patients treated with high-dose bolus IL2 and IFN", as 
reported in chapter 4. Despite pretreatment cardiac screening almost half of the 
patients exhibited myocardial injury. Four patients developed cardiomyopathy, one 
a myocardial infarction and one negative T-waves on the electrocardiogram. 
Another patient died of acute cardiac arrest. Echocardiography showed hypokinesis 
and decreased ventricular ejection fraction. Endomyocardial biopsies revealed 
edema, vacuolisation and degeneration of myocytes. It was concluded that 
treatment with a combination of high-dose IL2 and IFN", can induce severe and 
life-threatening cardiac toxicity. 
The incidence of thyroid dysfunction during IL2-based immunotherapy and the 
significance of abnormal thyroid function as a prognostic factor, that can predict a 
tumor response was analyzed in a group of 89 patients, receiving various treatment 
schedules, and the results are presented in Chapter 7. Twenty patients (22 %) 
developed thyroid dysfunction. The relationship between thyroid function 
abnormalities and cumulative dose of IL2 was of borderline significance, whereas 
the relationship with treatment duration was highly significant. In contrast with data 
from the literature no relationship between thyroid dysfunction and probability of 
response could be observed after adjustment for cumulative dose of IL2 and 
treatment duration. 
In Chapter 8 the present role of adoptive immunotherapy with IL2 and IFN", 
is discussed. Therapy with the cytokines IL2 and IFN", with or without LAK cells 
yields good results in a small proportion of patients, almost exclusively with 
metastatic renal cell cancer and melanoma. Tumor responses occur in 10-25 % of 
patients with 5-10% complete responses. Combination schedules or higher dose 
regimens do not improve the treatment results but do increase toxicity. 
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For improvement of these treatment results a more tumor-specific or tumor-
targeted immunotherapy strategy is essential. Innovative new treatment modalities 
that are now already available and may develop to important new immunotherapies 
in the near future, are gene modilled tumor-infiltrating lymphocytes, gene modifIed 
tumor vaccines, bispecific monoclonal antibodies and the chimeric T cell receptor. 
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De cytokinen interleukine-2 (IL2) and interferon-alpha (IFNa) hebben diverse 
immuunmodulerende en antitumor effecten. Bij patienten met kanker is van be ide 
eiwitten aangetoond, dat zij ieder afzonderlijk werkzaam zijn tegen uitgezaaide 
nierkanker en melanoom. Op grand van laboratorium onderzoek en op basis van 
resultaten van fase I studies bij patienten, is de veranderstelling naar voren 
gekomen, dat gecombineerde behandeling met beide cytokinen tezamen betere 
antitumor resultaten geeft dan behandeling met elk eiwit apart. Dit praefschrift 
beschrijft een aantal klinische studies over de toepassing van de combinatie IL2 en 
IFNa bij de therapie van patienten met uitgezaaide nierkanker en melanoom. 
Hoordstuk 1 geeft een kort overzicht van de belangrijkste 
imIl1uuI1modulerende, groeiremmende en antitumor effecten van IL2 en IFNa, 
zoals aangetoond in diverse laboratorium- en praefdier studies. De resultaten van 
monotherapie met IL2 of IFNa, zoals deze tot nu toe bereikt zijn, worden hierin 
samengevat. De redenen om IL2 en IFNa bij de hehandeling van kanker te 
combincren worden beschreven. 
In hoordstuk 2 worden onze eerste ervaringen beschreven met de 
gecombineerde toediening van IL2 en IFNa in twee verschillende schema's aan 
patienten met gemetastaseerd melanoom. De voorlopige resultaten lieten respons 
percentages zien van respectievelijk 21 % en 56%. 
Hoordstuk 3 bevat de eind analyse van een multicentrische fase II studie, 
uitgevoerd in patienten met gemetastaseerd melanoom. Patienten werden behandeld 
volgens het volgende schema; IL2 7.8 MIU/m'/dag continu intraveneus gedurende 
4 dagen samen met IFNa 6 MU/m'/dag, per subcutane toediening op dag 1 en 4. 
Een-en-vijftig patienten waren evalueerbaar voor respons en toxiciteit. Responsen 
werden gezien in 8 patienten (16%), 1 compleet (2%) en 7 partieei (14%). De 
mediane respons duur en de mediane overleving waren respectievelijk 8 en 11 
maanden. De meest voorkomende bijwerkingen waren koorts, koude rillingen, 
vermoeidheid, roodheid van de Imid, misselijkheid, braken en diarree. De eind 
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conclusie van deze studie was, dat dit schema van toediening van IL2 en IFNa, in 
een intermediaire dosis intensiteit, slechts een beperkte antitumor activiteit had en 
niet beter was dan monotherapie met IL2 aileen. 
De resultaten van twee schema's met hoge doses IL2 and IFNa, gegeven als 
intraveneuze bolus injecties aan patienten met gemetastaseerd melanoom, zijn 
samengevat in hoofds!ul, 4. De patienten kregen gedurende iedere kuur IL2 en 
IFNa toegediend door mid del van intraveneuze injecties in een dose ring van 
respectievelijk 11.7 MIU/m' en 3 MU/m', elke 8 uu!'. In het totaal werden 3 kuren 
gegeven. In het eerste schema bedroeg de behandelingsduur 5 dagen per kuur. Van 
de 17 evalueerbare patienten, bereikten er 2 (12%) een complete en 5 (29%) een 
partiele respons (totale respons percentage 41 %). Echter, dit gedeelte van de studie 
werd voortijdig gesloten als gevolg van het optreden van ernstige cardiotoxiciteit 
(41 %) en neurotoxiciteit (28%). Vervolgens werd in het tweede dee I van de studie 
de duur van een kuur ingekort van 5 naar 3 dagen. Van de 25 evalueeroare 
patienten in dit schema kregen er 5 een respons, (20%, allen partieel). De met dit 
schema samenhangende toxiciteit was hanteerbaar. Concluderend, gaf het 5-daagse 
schema met hoge dosis IL2 and IFNa een relatief hoog respons percentage, maar 
veroorzaakte het een onacceptabele toxiciteit. Met een gemodificeerd 3-daags 
schema vielen de bijwerkingen mee, maar waren de behandelingsresultaten niet 
beter dan met IL2 monotherapie. 
In hoofds!uk 5 worden de resultaten gerapporteerd van een intensief 
immunotherapie regime bestaande uit IL2, IFNa en Iymfokine-geactiveerde killer 
(LAK) cellen. Deze behandeling werd gegeven aan patienten met uitgezaaide 
nierkanker. Twee-en-zeventig patienten werden in de studie opgenomen, waarvan 
17 in het eerste deel van de studie om de haalbaarheid van het behandelingsschema 
te onderzoeken (protocol I) en 55 in het tweede deel ter beoordeling van het 
antitumor effect (protocol 2). De behandeling bestond uit IL2 18 MIU/m'/dag, dag 
1-5 en 12-15 door middel van continue infusie en IFNa 5 MIU/m2/dag, dag 12-15 
als intramusculaire injectie. LAK infusies werden gegeven op dag 12-14. In 
protocol 2 werden ook IFNa injecties gegeven op dag 1-5. In principe kregen de 
patienten twee van deze inductiekuren, waarna bij een gunstig resultaat de 
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behandeling met maximaal 4 onderhoudskuren kon worden gecontinueerd. Van de 
patienlen in prolocol 1 kregen er 3 een complele en I een parliele respons (respons 
percentage 24 %). De mediane respons dum en de mediane overleving waren 
respeclievelijk 18 en 14 maanden. De bijwerkingen waren alleszins aanvaardbaar 
en dosis reduclies waren niel nodig. Het res pons percenlage in prolocol 2 bedroeg 
37%, mel 6 complete en 13 parliele responsen. De mediane duur van de respons en 
de mediane overleving waren respeclievelijk 11 en 17 maanden. De loxicileil in 
protocol 2 was echler aanzienlijk, drie palienten overleden, mede als gevolg van de 
behandeling. Slechts ongeveer 40-50% van de geplande doseringen aan IL2 en 
IFNa kon worden gegeven. De conclusie van deze sludie was, dal de loepassing 
van gecombineerde inlensieve schema's mel IL2 en IFNa voorlopig niet 
gerechlvaardigd is loldal we beter in slaat zijn de subgroep van palienlen Ie 
idenlificeren, die een langdurige overleving bereiken met deze therapie. 
Hoofdstuk 6 geeft een gedetailleerde beschrijving van een aantal gevallen van 
ernstige cardioloxicileit, dat zich voordeed in een groep patienlen, behandeld met 
hoge doses IL2 en IFNa in het schema lOals beschreven in hoofdstuk 4. Ondanks 
uitvoerige cardiale screening voorafgaande aan slarl van de Iherapie ontwikkelde de 
helft van de patienten hartschade. Vier palienlen kregen een cardiomyopathie, een 
een myocard infarcl en een ander ontwikkelde negalieve T -Ioppen op hel 
elektrocardiogram. Een zevende patient overleed aan een acule harlslilsland. 
Echocardiografisch onderzoek liet verminderde wandbewegingen van de ventrikels 
en een verlaagde ejectiefractie zien. Endocard bioplen loonden oedeem, vacuolisatie 
en degeneralie van myocyten. Concluderend kan behandeling met hoge doses IL2 
en IFNa leiden tot ernslige en levensbedreigende cardiotoxiciteit. 
Hoofdstuk 7 beschrijft een onderzoek naar het voorkomen van 
schildklierfuncliesloornissen gedurende behandeling met immunotherapie met IL2 
in een groep van 89 patienlen. Tevens werd gekeken naar de mogelijk 
voorspellende waarde van het ontstaan van een gestoorde schildklierfunclie voor het 
oplreden van een antitumor respons. Twintig patienten (22%) onlwikkelden 
schildklierdysfunctie. De relalie tussen het ontstaan van schildklierfunctie 
afwijkingen en de cUll1ulatieve dosis IL2, aan een patient toegediend, bleek net niet 
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significant te zijn. De relatie met de duur van de behandeling was zeer significant. 
De conclusies waren, dat schildklierdysfunctie een frequente complicatie van IL2 
behandeling was en, dat in tegenstelling tot eerdere literatuur gegevens er geen 
relatie kon worden vastgesteld tussen het optreden van een afwijkende schildklier 
functie en de waarschijnlijkheid van een respons na conectie voar cumulatieve 
dosis IL2 en behandelingsduur. 
In hoofdstuk 8 wordt de huidige rol van adoptieve immunotherapie met IL2 en 
IFN" in de behandeling van solide tumaren besproken en bediscussieerd. 
Behandeling met IL2 en IFN" met of zander LAK cellen geeft gunstige resuitaten 
bij een beperkt aantal patienten, voornamelijk patienten met uitgezaaide nierkanker 
en melanoom. Tumor responsen worden waargenomen bij 10-25% van de 
patienten, waarvan 5-10% compleet. Combinatie schema's of hoge doses regimes 
verbeteren de resuitaten niet maar Ieiden weI tot meer bijwerkingen. 
Om tot verbetering van de behandelingsresultaten van immunotherapie te 
komen is een meer tUll1or-specifieke en tumor gerichte strategie essentieel. 
Voorbeelden van nieuwe veelbelovende technieken zijn genetisch gemoditiceerde 
tumor-infiltrerende lymfocyten, genetisch gemodit1ceerde tumor vaccins, 
bispecifieke monoclonale antilichamen en de chi mere T eel receptor. De eerste 
ervaringen hiermee zijn bijzonder interessant en met toch zekere verwachtingen 
wordt uitgekeken naar meer definitieve resultaten van Iopende studies. 
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